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Abstract 
Spherical vesicles consisting of phosphatidylcholines in which diacetylene groups have 
been inserted in the hydrocarbon tail centers give rise to hollow cylindrical tubes, known as 
“tubules”.   The study of tubules has become an area of intense interest in recent years due to 
their unusual morphology, which raises several profound theoretical issues and suggests their use 
in a variety of applications.  Tubule hollowness suggests medical and industrial encapsulations as 
well as filtration and purification applications.  These potential uses, e.g., for drug and gene 
delivery, requires optimization of their morphology for the application.  Tubules have many 
technologically desirable properties, such as a very narrow distribution in diameter and length.  
The ability of the hydrocarbon tails' diacetylene groups to be polymerized suggests post-
assembly modifications may be possible.   Tubules are also susceptible to alignment with electric 
and magnetic fields, and being able to manipulate tubules in these ways can lead to a variety of 
new and innovative applications.  
 Our main area of study will be the exploration of tubule formation mechanisms via 
interactions with other molecules.  The phospholipid, DC(8,9)PC (1,2-bis(10,12-
tricosadiynoyl)sn-glycero-3-phosphocholine), is the most heavily-studied, and therefore serves as 
the standard to which comparisons can be made when the tubule-forming molecule is altered or 
when other components are added to the system.  These morphological changes are critical to 
one of our primary technological motivations, the encapsulation and delivery of drugs.  It is 
hoped changes of tubule size and shape resulting from either: a) the changes we make to the 
tubule-forming molecule; or b) the actions of the added molecule will yield; information about 
tubule internal structure.  For example, intrinsic curvatures, bending moduli and correlation 
lengths, physical properties that must play important roles in determining tubule morphology, 
 xvi
can be measured directly in these perturbed systems and compared to pure DC(8,9)PC tubules’ 
moduli. Studying the effects that certain molecules have on tubule formation can give us a better 
idea about the structural morphology and, most importantly, may allow optimization of that 
morphology for a particular application. 
 
 xvii
Chapter 1 
Background, Overview, and Research Synopsis 
1.1 Background  
1.1.1 Discovery of Tubules 
In 1989, Yager and co-workers discovered that phospholipids modified by the insertion 
of diacetylene groups spontaneously formed tubules, hollow cylinders of diameter 0.5 µm and 
lengths up to 200 µm.1-4  The prototypical diynoic lipid is the diynoic phosphatidylcholine 1,2-
bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine, DC(8,9)PC, (shown in Figure 1.1).  
Studies involving diynoic derivatives show that these molecules self-assemble to form 
microscopic hollow cylinders, with a helical trace evident on the exterior, creating a chiral object 
whose structure is similar to a paper drinking straw.  DC(8,9)PC and many of its derivatives are 
the simplest tubule-forming molecules (a growing number of compounds that form tubules are 
appearing in the literature), and this simplicity makes them the best candidates for studying the 
relationship between the molecule’s structure and its self-assembly behavior.  
 
Chiral Carbon
 
OPON
O
O
O
O
O
O
 
 
 
 
Figure 1.1  Chemical structure of 1,2-bis(10,12-tricosadiynoyl)sn-glycero-3-phosphocholine 
[DC(8,9)PC]. 
 
A number of non-diynoic compounds, including peptides,5-7 gemini surfactants,8-12 
multiple “-ene-“-containing compounds and others13,14 are currently being added to the group of 
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tubule-forming compounds that spontaneously form cylindrical structures; typically all these 
compounds produce cylinders of diameter ≈0.1 ≤ d ≤ ≈1µm, with lengths ranging from a few to 
several hundred µm.  Some of these structures are hollow, some are essentially solid, and some 
are cochlear.15  One is hard-pressed to identify what molecular features enable self-assembly 
behavior, and which features (if any) are shared within this class of molecules. 
In addition to its structural simplicity, DC(8,9)PC presents an excellent opportunity for 
self-assembly study because it forms relatively large (and hence easy-to-study microscopically) 
cylinders.  An important facet of DC(8,9)PC’s simplicity is that it differs from a manifold of 
natural and synthetic phosphatidylcholines that do not form tubules only by virtue of the diynes 
in its hydrocarbon tails’ mid-sections.  Clearly, these diynes are an “enabling” feature for tubule 
formation: saturated and semi-saturated DC(8,9)PC analogs do not form tubules. 
1.1.2 Chiral Sub-structure 
A simple cylinder is an achiral object, but DC(8,9)PC cylinders possess a chiral sub-
structure.  It is apparent that tubules form as a result of a flat ribbon winding helically (and hence 
chirally), resulting in the tubule “drinking straw” structure.  Since the energetics of phospholipid 
bilayer membrane self-assembly is driven largely by the shielding of hydrophobic hydrocarbon 
tails from the aqueous environment, one should expect bilayer sheets to be discs.  Circles are the 
minimum perimeter-per-area structure because they minimize the exposed hydrophobic tail at 
the bilayer’s edge.  At a non-zero temperature thermal effects cause the flat membrane to 
undulate; given sufficient membrane size and fluctuation, one should ultimately expect opposing 
edges of the sheet to encounter each other and fuse.  (Indeed, one should ultimately expect these 
energetically-expensive edges to vanish completely as the sheet bends to form a spherical 
vesicle.)  Justifying the energetics of the approximately 200:1 aspect-ratio ribbon that 
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subsequently winds to form a tubule is a significant theoretical challenge.8  Four apparently 
independent pathways to tubule formation are known, and no one has devised a way to isolate 
any single process.  Thermal analysis has proven to be problematic because of the inability to 
control the pathways by which tubules form.     
R-DC(8,9)PC tubule exteriors are always right-handed helices, while the mirror-image S-
DC(8,9)PC enantiomer always yields tubules possessing left-handed helical sub-structure.16  The 
remarkable correspondence between helical handedness (hereafter, “helicity”) and the 
molecule’s chirality suggests powerfully that tubule formation is directed by molecular 
chirality.17-19  The so-called “chiral packing” theory develops the idea that DC(8,9)PC’s chiral 
shape causes the “directors” -- molecules’ long axes -- of adjacent molecules in the tightly-
packed bilayer membrane to be tilted slightly with respect to each other, and this tilt is uniform 
in a given direction along the length of the membrane.  The propagation of this offset angle leads 
the membrane molecules to twist helically in a manner that ultimately winds to form closed 
cylinders, tubules.   
A competing, but less accepted, “chiral symmetry-breaking” theory asserts that the 
membrane ribbon chiralizes (that is, selects its helicity) randomly.20,21  To resolve which theory’s 
assumptions are correct, an achiral DC(8,9)PC isomer β–TFL was made by interchanging one of 
the ester-linked hydrocarbon tails attached to the glycerol backbone’s central carbon atom with 
the phosphocholine head group, forming a symmetric β-tubule-forming lecithin (β-TFL) that 
lacks a chiral center (see Figure 1.2).22  This compound formed tubules at the same yield and 
under the same conditions as DC(8,9)PC, proving that tubule formation is not dependent on 
molecular chirality, and that the process appears to be better-described by the more general chiral 
symmetry-breaking theory.  β-TFL produces an equal number of right and left-handed tubules.22  
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These results reveal that the chiral packing theory alone is not adequate to explain the tubule 
structure, and yet the chiral symmetry-breaking theory alone does not explain the remarkable 
helicity: chirality correspondence found with enantiopure R- or S-DC(8,9)PC.  
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Figure 1.2  Chemical structure of achiral DC(8,9)PC isomer, “β–TFL”. 
1.1.3 Tubule Formation 
Additional theoretical challenges in explaining tubule structure and formation result from 
the distinct, rather disparate physical processes by which tubules are seen to form:  we have 
observed three distinct phospholipid tubule formation mechanisms.  All three occur in ethanolic 
DC(8,9)PC solutions heated above 50oC that are cooled slowly (approximately 5oC/hour) to 
room temperature.  These solutions become turbid upon cooling to ~40oC; small angle x-ray 
scattering (SAXS) shows this turbidity to be a consequence of multilamellar vesicles; optical 
microscopy shows these vesicles to be of the usual spherical symmetry.  When the solution 
reaches room temperature, tubules form.  Approximately 90% of the lipid found as tubules 
ultimately precipitates as tubules, while the balance remains in clear solution at room 
temperature; no other self-assembly products are found.  Tubule self-assembly persists over a 
wide range of pH, solvent composition, and ionic strength. 
Tubules may also be prepared in an isothermal process, where dilute DC(8,9)PC lipid in 
pure ethanol is slowly titrated with water, in which the phospholipid is less soluble.  This 
solution also becomes turbid and tubules eventually precipitate.  An alternative to direct titration 
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involves putting the pure ethanol/DC(8,9)PC solution into a dialysis bag and placing this bag in a 
large water reservoir. 
 The thermal process is experimentally more accessible because temperature is easier to 
control on a microscopic scale than is solvent composition, e.g., via a hot stage-equipped 
microscope or a SAXS experiment conducted upon a sufficiently thin sample that is under 
computer-mediated temperature control.  For these technical reasons, the isothermal process’ 
kinetics have not been studied as thoroughly as those of the thermal process, and this process 
will not be discussed further, other than to say it produces the same product with about the same 
yield.  
In contrast, the thermal process has been extensively characterized by in situ Nomarski 
differential interference phase contrast microscopy (DIC) and SAXS probes, and its products by 
atomic force microscopy (AFM) and electron microscopy.  DIC has been particularly powerful 
in resolving the three tubule formation mechanisms, which we now summarize. 
1.1.3.1 Emergence from Vesicles 
Under conditions of ultra-slow cooling ( dT dt ≈  0.1 oC/hr), DIC reveals the dominant 
tubule self-assembly mechanism to be the rapid (≈1.0 µm/s) growth of helices from spherical 
multilamellar vesicles.23  SAXS shows the spherical vesicles to be in the chain-melted, 
disordered Lα phase, while the product tubules are in the chain-frozen, highly-ordered tilted Lβ’ 
phase as shown in Figure 1.3.24 
A. B. 
 
 
Figure 1.3  A.  Lα chain melted phase, B.  Lβ’ chain-frozen phase. 
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As mentioned above, DC(8,9)PC tubule size permits direct DIC microscopy observation 
of the process.  As the vesicle is cooled from the Lα phase, nodules appear on the surface of the 
vesicle; under conditions of ultra-slow cooling these nodules can persist for tens of minutes.  
Helical ribbons then abruptly begin to nucleate and grow from these nodules, and a typically a 
tangled “nest” of tubules form as all the material in the spherical vesicle converted to tilted Lβ’ 
phase tubules over the course of tens of seconds. These ribbon-like structures emerge and 
lengthen from the spherical vesicles as helices.  A second growth process is occurring 
simultaneously:  As the ribbons grow in length they also widen slowly, until the ribbon’s 
opposing long edges meet, thereby forming a continuous cylinder.  While this meeting of the 
edges seemingly abolishes ribbon edge exposure to the aqueous environment and the associated 
energetics expense, the perseverance of the helical ridge makes evident these edges do not fuse.  
While this may be an effect of the tubule’s non-fluid, chain-frozen Lβ’ phase, several examples 
are known where the helically-would ribbon’s opposing edges do not meet.  For example, a 
considerable portion of DC(8,9)PC microstructures made in solutions where ethanol is replaced 
with isopropanol are found as “open” helices,17 and approximately 10% DC(8,9)PC phosphonate 
tubules are also found in this state under conditions where all DC(8,9)PC microstructures are 
closed cylinders.25,26  Also, a number of unrelated tubule-forming systems have exhibited open 
helical structures.27,28  As amphiphilic structure formation is driven initially by reducing the 
hydrocarbon tail/water interaction, the widespread exposed hydrocarbon tail along the extended 
ribbon edge remains a difficulty when explaining the stability of these open helices.  (Later, the 
“tubelet”, a structure discovered in this lab, will be discussed, that explains the stability of the 
long ribbon and the persistence of the helical trace upon the tubule exterior.) 
 6
 SAXS shows that DC(8,9)PC tubules formed in ethanolic solutions are multilamellar, i.e., 
they are composed of coaxially nested cylinders (shown in Figure 2.1);24 DIC permits the direct 
observation of the outer tubule layers’ formation and shows that these outer cylinders form from 
a very different mechanism than do the tubules’ innermost cylinder, involving material transport 
between the solution and the condensed phase, in contrast to the inner cylinder’s growth from a 
large reservoir of super-cooled Lα phase spherical vesicles.23   
 DIC shows that several minutes after all Lα phase DC(8,9)PC spherical vesicles have 
been converted to Lβ’ phase tubules, a growth front propagates along the now continuous-walled 
cylinder’s axis.  It is apparent that the Lβ’ phase cylinders formed from the spherical Lα phase 
vesicles now serve as nucleation sites for dissolved phospholipid in the still-cooling saturated 
solution.  At v ≈ 0.1µm / sec, this outer cylinder’s growth is an order of magnitude slower than 
that of the core’s growth.    
 The sphere-to-tubule transition is thermally reversible, but substantial thermal hysteresis 
is observed.  In the spherical, Lα phase to helical Lβ’ phase conversion, under ultra-slow cooling, 
tubule nucleation and growth typically occurs two or three degrees Celsius below the tubule 
melting temperature.  This means that the rapidly formed tubule cores form from super-cooled 
Lα phase spherical vesicles, while the much slower outer layer growth appears to be quasistatic 
in nature.   
The discrepancy of outer and inner cylinders growth rates is reflected most surprisingly 
in their chiral sub-structure: AFM probes of the quickly-formed tubule core’s helicity shows that 
they are almost equally divided between left and right-handed helicities, in marked contrast to 
the absolute uniformity of the slowly-formed outer cylinders’ helicity, which corresponds to the 
chirality of the DC(8,9)PC used.23  This experiment was done by preparing a glass slide whose 
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entire surface was covered with air-dried tubule suspension.  This glass slide was then slowly 
dipped over the course of about 5 seconds into a 90% ethanol/water solution.  The slide was then 
quickly withdrawn and swirled in a 4 liter beaker containing pure water.  The 90% ethanol 
solution dissolves tubules at room temperature, but the slow lengthwise dipping of the glass slide 
into the ethanolic solution beaker created an “exposure gradient” – the bottom of the slide 
endured 10 seconds of exposure to this solution, while the top part of the slide endured only 
about ½ a second.  It was found that the portion of the slide that endured the most exposure to the 
solution was wiped clean of tubules and residue, while the portion of the slide that endured the 
briefest exposure showed no real signs of the solvent’s effects.  Lying between these two 
extremes were regions where the solvent had sufficient time to strip away tubule exteriors, 
revealing the core.  While the counting statistics are poor, it was clearly evident that while R-
DC(8,9)PC tubule exteriors always possess right-handed helicity and the S-DC(8,9)PC 
enantiomer always produces left-handed helicity, the inner cylinder helicities are apparently 
random, hence determined kinetically during the rapid conversion of the super-cooled spherical 
vesicle to cylinder. 
A variation of this experiment was to use water-immersion Nomarski optics and add tiny 
amounts of pure ethanol to the droplet being examined.  Once again, the counting statistics are 
poor, but there is clear evidence of violations of the chirality/helicity correspondence required of 
the chiral-packing class of theories. 
The presumed absolute correspondence between molecular chirality and cylinder helicity, 
as seen on the tubule exterior essentially required a “chiral-packing” theory, in which the 
mesoscopic scale (≈1 µm) helical winding is ultimately traceable to the molecule’s chirality.  
The observation of enantiopure tubule cores possessing the “wrong” helical sense of handedness 
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breaches this association, and the robust formation with the achiral DC(8,9)PC isomer (Figure 
1.2) shows that the chiral packing theory must be re-evaluated.  “Re-evaluated” rather than 
discarded, because as mentioned above, the chiral symmetry-breaking theory alone is insufficient 
to describe the dramatic influence of molecular chirality upon the tubule exterior.   
1.1.3.2 Growth from Solution 
 The second tubule formation mechanism is growth directly from solution, i.e., in cooling 
saturated DC(8,9)PC solution, as in the previous mechanism, but in regions where spherical 
vesicles are absent.  This mechanism has been observed only a few times and is therefore 
presumably a minor contributor to the product.  The tubules forming under this mechanism 
appear to grow at both ends, at apparently the same v≈0.1µm speed as the ensheathment of the 
tubules described in the previous mechanism, and concurrently with tubule ensheathment.  
Because these tubules appear to grow at the same time and same rate as the multilamellar 
tubules’ outer layers, one can tentatively conclude that this mechanism is essentially the same 
first-order phase transition of solvated molecules to the Lβ’ phase that occurs during the 
formation of multilamellar tubules’ outer layers. 
1.1.3.3 Detachment from Sheets 
 The final tubule formation mechanism appears to be a minor contributor to tubule 
formation, as in the case of tubule growth from solution.  Indeed, it is possible this mechanism 
does not occur at all in the bulk solution in which tubules are prepared, and only under ultraslow 
cooling of lipid solutions undergoing optical microscopy.  This third process begins with the 
formation of large parallelogram-shaped phospholipid multilayer sheets, on the order of 300 µm 
x 100 µm, on the surface of the glass microscope slide.  As seen in Figure 1.4, these sheets 
contain striations parallel to their long edges, and in time (typically about a second) five to 
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fifteen parallel phospholipid tubules form through the edgewise detachment from these striations, 
with the resulting ribbon winding helically, growing in length, and traveling perpendicular to it’s 
long axis, as if tethered to the large surface-bound sheet.  This process happens over the course 
of ~1 s.  While this mechanism appears to be a minor contributor to the overall product, it is 
important because it is very similar to one proposed in 1996 by Selinger and coworkers for 
tubule formation in bulk solution from large spherical vesicles or flat sheets.18  Consequently, the 
possibility that this mechanism is more dominant in bulk than our infrequent observations of it 
would suggest cannot be dismissed.  
 
 
 
 
 
 
 
Figure 1.4  Nomarski DIC micrograph of DC(8,9)PC tubule array formed by the edgewise 
separation and helical winding of 1 µm-width ribbons from a large (300 µm x 100 µm), 
surface-bound parallelogram phospholipid multi-layer sheet (marked by the arrow).  Note 
the faint line running along the sheet’s long axis.   
 
1.1.4 Theoretical Challenges 
Tubules are thus seen to form through at least three very different mechanisms: 1) 
emergence from spherical Lα phase multilamellar vesicles cooled below the Lβ’ phase melting 
temperature; 2) as “free-standing” structures formed through the first-order crystallization of 
lipid from the cooling saturated lipid solution; and, 3) the edgewise separation and helical 
winding of ribbons from large, surface-stabilized multilamellar sheets that form as saturated lipid 
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solutions cool.  All mechanisms involve the helical winding of ribbon-like structures and 
“barber-pole” windings are evident on tubules formed by these mechanisms.   
 An adequate theoretical model does not exist for explaining the different tubule structures 
or their formation through the diverse mechanisms.  Among the questions a satisfactory theory 
must address for all tubule formation mechanisms include how a ribbon having a 200:1 aspect 
ration spontaneously forms, particularly in view of the highly unfavorable energetics of the 
extended exposed hydrophobic edge, and how this ribbon chiralizes and winds to form a closed 
cylinder.  In Chapter 3 a structure discovered in this laboratory,29 the “tubelet”, will be described, 
that resolves many of the theoretical problems in tubule formation theory, and that has profound 
technological consequences, especially for the central topic of this dissertation, drug 
encapsulation.        
1.2 Overview 
1.2.1 Phosphonates 
Having described the known tubule formation processes, we now consider tubules made 
from the different molecules of Figure 1.5 which all share the apparently necessary (for 
phosphatidylcholines, at least) diynoic tails, but differ in their hydrophilic headgroups.   
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Figure 1.5  Chemical structure of A. S-“C4” DC(8,9)PC phosphonate derivative and B. R-
“C3” DC(8,9)PC phosphonate derivative. 
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1.2.1.1 C4-phosphonate 
As the glycerol backbone has a definite influence on tubule morphology (R-DC(8,9)PC 
forms right-handed tubules, while S-DC(8,9)PC forms left-handed tubules),16 it is important to 
study modifications made to this portion of the molecule to see how tubule morphology is 
altered.  The outcome of replacing the oxygen linkage to the phosphate group with a methylene 
group (-CH2-) created a new tubule-forming phospholipid, “C4-phosphonate”.25 The 
phosphonate was selected because many phosphonate analogues of phosphorylated natural 
products function as inhibitors for enzymes for which the natural product is a substrate.30,31  
Given enzymes’ well-known substrate specificity, and their acceptance of phosphonate analogs 
as substrate, the (-CH2-)/O substitution seemed like a change that could be sufficiently small that 
tubule-forming ability would be conserved, and would be small enough that any observed change 
could be considered significant.  
It was found that the C4-phosphonate fashions tubules in the same manner as DC(8,9)PC: 
1) the ethanol/water ratios for optimal yields are alike; 2) tubule yields are 90%; and, 3) the 
tubule-forming temperatures for the compounds are within 1oC of each other.  Also, tubule 
lengths are very comparable; DC(8,9)PC and C4-phosphonate have tubule lengths of ~26 µm 
and ~23 µm respectively.  Despite the similarities, there are some remarkable differences:  1) 
C4-phosphonate tubules have diameters of ~1 µm, twice that of DC(8,9)PC; 2; they have a 
greater propensity to flatten when placed upon a substrate – that is, they seem to be less rigid 
than DC(8,9)PC tubules; and most consistent with this change, 3) while the phosphonate tubule 
diameter doubled, there is a decrease in the number of coaxially nested cylinders; that is, 
phosphonate tubule wall thickness is half that of DC(8,9)PC tubules.   
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1.2.1.2 C3-phosphonate 
Another phosphate analogue was synthesized, since the substitution of the phosphoryl 
oxygen by a methylene group was successful in altering tubule morphology.  The new molecule 
was made by removing the phosphonate oxygen atom.  Since this analogue has a 3-carbon 
glycerol backbone, it is referred to as “C3-phosponate”.26   
 Tubule formation occurs in the same manner as DC(8,9)PC and the “C4” phosphonate, 
where the solvent ratios, tubule yields, and tubule-forming temperatures are similar.  As with the 
“C4” phosphonate, there was also a 2-fold increase in tubule diameter, yielding tubules with ~1 
µm diameters but with shorter lengths of ~16 µm.   
1.2.1.3 Conservation of Interlamellar Spacing 
These phosphonate molecules reveal a most interesting phosphatidylcholine tubule 
property, namely, that interlamellar spacing, as determined by SAXS, is a tightly conserved 
quantity.  DC(8,9)PC tubule interlamellar spacing is 64.7 Ångstroms, while the two DC(8,9)PC 
phosphonate derivatives (whose diameters are twice that of DC(8,9)PC) have interlamellar 
spacings of 65.3 and 62.6 Ångstroms.25,26  These measurements are consistent with a long-axis 
(director) tilt of 32o from the membrane normal for completely expanded, all-trans methylene 
molecular configurations as projected by Caffrey et al.32  The few Ångstroms’ variation between 
different molecules’ tubules interlamellar spacings are small in comparison to the two-fold 
changes in tubule diameter.  The SAXS correlation lengths ξ, which is a measure of tubule wall 
thicknesses, are nearly halved from the DC(8,9)PC 430 Ångstroms to 210 Ångstroms as the 
tubule diameters doubled.26 
 Tubules made from the phosphonates of Figure 1.5 deposited onto glass substrates 
sometimes partly unravel at their ends, permitting direct measurement of membrane thickness by 
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AFM.  Investigation of these tubules on flat substrates shows that the flat, unraveled portions 
have heights approximately twice that expected of a single bilayer at the known long-axis tilt of 
32o (Thomas, unpublished result). Accordingly, these tubule walls must consist of two bilayers 
(that is, four monolayers).  Since phosphonate tubule wall SAXS correlation lengths are half that 
of DC(8,9)PC, we conclude DC(8,9)PC tubule walls are four bilayers thick.  AFM measurements 
provide confirmation of SAXS results.  
1.2.2 Phospholipid/Protein Cones 
DC(8,9)PC tubule-forming solutions where a protein, lysozyme, has been added exhibits 
the same strict conservation of bilayer spacing and tubule wall thickness.  The 
DC(8,9)PC/lysozyme mixture’s prevailing products are that of a gently tapered cone instead of 
the expected hollow cylindrical tube.33  Although, some undistorted tubules are present, the 
majority in this protein-containing solution are conical.  Like DC(8,9)PC tubules, these cones 
have helical ridges, but they are more distinct.  DIC video microscopy shows cone formation to 
be very similar to protein-free tubule formation, the principal difference being that cones 
emanate from proteinaceous nodules that precipitate early in the cooling cycle, rather from the 
Lα phase spherical vesicles of the protein-free system.  While DC(8,9)PC tubule cycle reverses 
back to spherical vesicles when reheated, DC(8,9)PC/lysozyme systems do not convert back to 
vesicles upon heating.  When cones are subjected to reheating they seem to dissolve back into 
solution, suggesting spherical vesicles do not form; however, cones do re-appear when the 
solution is cooled again.  Also, cone formation occurs ~10oC higher than that of DC(8,9)PC 
tubule solutions free of protein.   
Spatially-resolved energy dispersive x-ray spectroscopy (EDS) tuned to the protein’s 
sulfur-bearing cysteine residues shows the protein is disseminated uniformly along the cone 
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length, but is not found elsewhere on the electron microscopy substrate, indicating that lysozyme 
is associated with the lipid.33  SAXS results confirm that cones also consist of four bilayers 
spaced at 66.2 Ångstroms, very close to the interlamellar spacing of 64.7 Ångstroms for protein-
free tubules.  The addition of protein disrupts normal tubule formation and causes cones to form 
instead of cylinders, suggesting that tubule morphology may be optimized for a specific 
application through the addition of such agents, or common polymers such as polyethylene oxide 
(PEO) or polyethylene glycol (PEG).     
1.2.3 Tubules with Tunable Diameters   
Diacetylenic lipids produce 0.5 µm diameter tubules no matter what the length of the acyl 
chain or the placement of the diacetylene groups; however, a recent study using a mixed lipid 
system composed of short-chain saturated phospholipid “spacers” and diacetylenic phospholipids 
demonstrates another approach that could avoid the need to resort to costly and time-consuming 
syntheses to control tubule diameter.34  A decrease in tubule diameter leads to higher-aspect ratio 
structures.   
Control of tubule diameter will have a major impact on technologies that may use tubules 
for their aspect ratios. Two examples spring to mind:  1) the release of encapsulated materials 
from a tubule will undoubtedly depend upon the tubule diameter; and 2) as discussed below, the 
somewhat surprisingly sole determinant of tubules’ effective aerodynamic diameter is the 
tubule’s diameter - - tubule length plays almost no role in tubule aerodynamic behavior. 
Mixtures of diacetylenic phospholipids DC(m,n)PCs and saturated lipids DC(m`)PCs, 
reveal a connection between the n segments of the acyl chains in the diacetylenic 
phosphocholines and the diameter of tubules produced from these lipid mixtures.34   
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1.2.3.1 Result of Acyl Chain Length of Saturated Spacer Lipids 
Singh et al. studied lipid mixtures prepared with DC(8,9)PC and DC(m`)PC ranging from 
8-12 carbon long acyl chains in order to determine the effects that the chain length would have 
on tubule diameter.34  Tubule diameters were measured immediately after tubule formation was 
complete (4oC), after annealing for 105 days (4oC), and after 120 hours at room temperature.  
Both DC(6)PC and DC(8)PC are unable to conceal the functionality of the diacetylene groups in 
DC(8,9)PC from interacting with neighboring diacetylene groups, and tubules with smaller 
diameters resulted from secondary interference effects.  After annealing, the diameters remain 
unchanged, within error, but after storing at room temperature, DC(6)PC-doped specimens 
formed helical ribbons and DC(8)PC-doped solutions’ mean tubule diameter increased.  
DC(9)PC and DC(10)PC hydrocarbon tails, however, are long enough to interact with the 
diacetylenes, or perhaps interfere with diyne/diyne interactions present in the tubule 
phospholipid bilayers, and tubules with much larger diameters form.  Upon room-temperature 
annealing, however, these larger diameters decrease to approximately the usual DC(8,9)PC 
diameter after annealing, making these tubules technologically appealing.  The DC(9)PC spacer 
tubule morphology equilibrates at room temperature, while the DC(10)PC forms vesicles.  The 
measurements for these diameters are shown in Table 1.1, showing that tubule diameter can be 
controlled by the length of the acyl chain in the spacers and annealing can lead to desirable 
properties. 
1.2.3.2 Result of Diacetylenic Acyl Chain Length 
 Using the saturated spacer lipid, DC(7)PC, which equals the m segment (m = 8) of 
DC(m,n)PC, the effect of the n segment was determined.34  For n = 9, 11, and 13, diameter sizes 
were approximately 55, 63, and 108 nm respectively.  The results reveal that as the n segment 
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Table 1.1  Tubule diameters as a result of acyl chain length.34 
 
DC(n)PC Tubule Diameter (nm) 
Immediately (4oC) 
Tubule Diameter (nm) 
105 Days (4oC) 
Tubule Diameter (nm)  
120 h ( 25oC)  
DC(6)PC ~57 ~58 ~30 Helical Ribbons 
DC(8)PC ~52 ~52 ~89  
DC(9)PC ~124 ~63 ~75  
DC(10)PC ~93 ~55 ~167 Vesicle 
increases so does the tubule diameter.  Similar studies where the m and m` segments were 
increased by two display the same results: diameter increases as the n segment increases.  Both 
studies also prove that the diameter size is independent of the total diacetylenic acyl chain length.  
For instance, DC(8,11)PC and DC(10,9)PC have the same amount of carbons in their acyl chains 
and have approximately the same diameters of their tubules (~70 and ~69 nm) after annealing. 
1.2.3.3 DNPC 
 A mixture of DC(8,9)PC and the short chain saturated lipid 1,2-bis(dinonanoyl)-sn-
glycero-3-phosphocholine, DNPC, yields tubules with diameters ranging from 50-60 nm.35  The 
addition of DNPC also increases the efficiency of polymerization, which can be important in 
mechanical as well as encapsulation (especially subcutaneous injection) applications.  
Suspensions of DNPC/DC(8,9)PC held at room temperature for longer period of time show that 
tubules convert to a network of entangled ribbons. 
 The annealing that occurs in these multi-component lipid membranes underscores the 
metastable nature of the initial tubule formation.  In other words, tubule formation is clearly 
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kinetically-driven, and the subsequent annealing is presumably a tendency towards the 
thermodynamically-stable product. 
1.2.4 Positioning and Alignment 
 The assembly of tubules into patterns on substrates is key in cultivating some of their 
potential applications.  Zhao et al. discovered that by combining dewetting and microfluidic 
networks, DC(8,9)PC can be aligned into two-dimensional ordered arrays onto glass substrates.36  
The capillary force induces a flow that pulls tubules into the microfluidic network and aligns 
them in the channels.  A patterned gold (Au) substrate with alternating 1-dodecanethiol (DDT) 
monolayer and Au stripes was made using a polydimethylsiloxane (PDMS) stamp.  The 
alternating hydrophilic and hydrophobic stripes allow for selective positioning of the tubules; the 
tubules adsorb on the hydrophilic Au stripes in the stripe direction as a result of the 
phosphocholine group, which is hydrophilic.  The resulting tubules remain consistent with 
normal tubule’s morphology, suggesting aligned tubules are not deformed in the process.  Some 
of the factors effecting tubule alignment include withdrawal rate, moving contact line, and 
adsorption time.  As the withdrawal rate increases, the angular distribution becomes restricted.  
The aligned tubules are perpendicular to the contact line because of surface tension.  The 
quantity of aligned tubules also increases as the adsorption time increases.  The ability to align 
tubules in large amounts onto substrates will enhance their use for a number of applications.   
1.2.5 Bending and Radial Deformation of Tubules on SAM 
 Droplets of DC(8,9)PC tubule solution air dried on hydrophobic DDT self-assembled 
monolayers undergo an interesting morphology change from a straight cylinder to a cylinder bent 
into a circular arc and can form a near spherical configuration.37   These tubules typically have 
persistence lengths of ~41 µm.  Several tubules so bent can be positioned to fashion an annular 
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structure.  In contrast, when DC(8,9)PC tubule solution droplets are dried on a hydrophilic Au 
surface, they quickly wet the surface and do not form curved tubules.  A shrinking contact line as 
the droplet desiccates is what causes this curve in the tubules, and it is a gradual process since 
the exterior remains smooth, with no apparent cracking.  Being able to understand the 
mechanical properties of tubules is vital for application development.   
1.2.6 Templated Synthesis 
The narrow distribution in diameter and length of tubules could lead to their use as 
templates for growth of inorganic salts, organic crystals, and polymers.  Templated synthesis can 
provide a means to control the resulting crystalline material or polymer structure and 
morphology.  Block copolymers,38 lipids,39 and liquid crystals40 have been used as templated 
media due to their highly organized structures, making DC(8,9)PC tubules also a great candidate 
for templated synthesis.  The templated synthesis of the conducting polymer, polypyrrole (Ppy), 
from a solution of DC(8,9)PC lipid tubules has been reported.41  The Ppy strand morphology 
progression occurs along the edges or seams of the tubule and not on the tubule surface.  The 
width of the Ppy strand is dependent on polymerization times, illustrating the ability to control 
resulting properties of this templated synthesis.  Tubules that have not completely formed 
(twisted ribbon-like structures or open tubules) have two parallel edges where the Ppy strands 
grow and trace each other.  Fully formed tubules have one Ppy strand that aligns on the surface 
in a helical fashion, along the barber-pole winding.  Ppy rings are often found at the end of the 
tubule, even on tubules where Ppy strands have not formed along the edges or seams.  Since the 
reaction could transpire either along the edges or on the surface, what causes Ppy strands to 
selectively grow along the edges?  According to the twisted bilayer ribbon theory, the edges 
consist of exposed hydrophilic regions; therefore, the acetylene groups may contribute to the 
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adsorption of Ppy onto the edges.  It may also be the favored site because of the high surface 
energy related to the curved edges.  Whatever the circumstances, the edge is the preferred 
location for the polymerization of pyrrole using tubules as a template.   
1.3 Research Synopsis  
The potential for technological applications is apparent immediately, and suggested 
tubule uses include: a substrate for the helical crystallization of proteins, templated synthesis of 
inorganic salts, organic crystals, and drug encapsulation.  This dissertation will focus primarily 
on two things:  Probing the relationship between the DC(8,9)PC molecular structure and the 
morphology of its self-assembly products, and in a practical vein, how such modifications might 
lead to their optimization for the application of drugs.  We describe a previously unobserved 
structure, the “tubelet”, in Chapter 3, encapsulation of several drugs (Chapter 4), addition of co-
surfactants (Chapter 5), and chemical modifications made to DC(8,9)PC (Chapter 6). 
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Chapter 2 
Materials and Methods 
2.1 Materials 
 1,2-bis(10,12-tricosadiynoyl)sn-glycero-3-phosphocholine (DC(8,9)PC) [Catalog # 
870016, Avanti Polar Lipids, Inc.], absolute ethanol [AAPER Alcohol and Chemical Company], 
distilled water, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) [Catalog # 850725, 
Avanti Polar Lipids, Inc.], lysozyme (from chicken egg white) [CAS # 12650-88-3, Sigma], and 
cholesterol [CAS # 57-88-5, Aldrich, 99%],  were used as received.   
Chemotherapy agents, carboplatin, methotrexate, and mitoxantrone, were fresh, surplus 
clinical materials supplied by Drs. Neal Mauldin & David Hunley of the LSU Veterinary School.  
These clinical materials were aqueous solutions; pure crystalline carboplatin was provided by 
Spectrum Pharmaceuticals, Irvine, CA. 
Materials used in syntheses (described in Chapter 6) include glycerol [CAS # 56-81-5, 
Sigma, 99%], acetone [CAS # 67-64-1, Aldrich, 99%], p-TsOH [CAS # 9192-52-5, Aldrich 
98.5%], diethylchlorophosphate [CAS # 814-49-3, Aldrich, 97%], ethyl ether [CAS # 60-29-7, 
Aldrich 99.7%], pyridine [CAS # 110-86-1, Aldrich 99.8%], oleic acid [CAS # 112-80-1, Sigma-
Aldrich, 99%], linoleic acid [CAS # 60-33-3, Sigma, 99%], γ-linolenic acid [CAS # 506-26-3, 
Sigma, 99%], sodium bicarbonate [CAS # 144-55-8, Aldrich 99.5%], chloroform [CAS # 67-66-
3, Aldrich 99%], potassium carbonate [CAS # 584-087, Aldrich 99.99%], sodium sulfate [CAS # 
7757-82-6, Aldrich 99%], and 1,3-dicyclohexylcarbodiimide [CAS # 36049-771, Aldrich 99%], 
were used without further purification.  Methylene chloride [CAS # 75-09-2, Aldrich 99.5%] was 
distilled over calcium hydride.  Ethyl acetate [CAS # 141-78-6, Aldrich 99.8%] and hexane 
[CAS # 110-54-3, Aldrich 95%] were distilled over sodium metal.   
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2.2 Methodologies 
2.2.1 Tubule Stock Solution Preparation 
 A stock solution of tubules was prepared by adding DC(8,9)PC lipid to a mixture of 
ethanol and water (at various ratios) at a concentration of 1mg of lipid/ml of solvent.  The lipid 
was dissolved by heating to 50oC while vigorously stirring until the solution became clear.  The 
solution was slowly cooled back to room temperature. It first becomes turbid as it enters the high 
temperature spherical vesicle phase, where the phospholipid is in the Lα phase, or chain-melted 
phase. Upon cooling further, the low temperature Lβ’ phase is entered, which is the time when a 
white precipitate of tubules form from a now-clearing solution.  This so-called “thermal” tubule 
formation process is shown schematically in Figure 2.1.  
2.2.2  Protein-Modulated Tubules 
 Lysozyme in the amount of 1 mg was added to 1ml of stock solution of DC(8,9)PC (with 
an ethanol to water ratio of 90:10 v:v).  This mixture was then taken through the standard 
thermal tubule formation cycle.  As before, upon cooling the solution became turbid, and 
clarifies upon further cooling as tubules precipitate.   
2.2.3 Addition of Chemotherapy Agents 
 The chemotherapy agents (methotrexate, mitoxantrone, and carboplatin) were added to 
the stock solution of DC(8,9)PC (with an ethanol to water ratio of 75:25 v:v) at the supplied 
clinical concentrations.  Once a drug was added to the stock solution, it was subjected to the 
standard thermal cycle, heating to clarity and cooling back to room temperature.  Turbidity 
indicates the formation of light-scattering structures, e.g., the spherical vesicles, but tubule 
formation is certain only when a precipitate has formed and it is microscopically examined for 
the presence of tubules.   
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Figure 2.1  Tubule preparation. 
 
2.2.4 Addition of DOPE and Cholesterol 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and cholesterol were added to 
the stock solution of DC(8,9)PC (with an ethanol to water ratio of 75:25 v:v) at various 
concentrations.  Once DOPE and cholesterol were added to the stock solution, it was heated to 
clarity and cooled back to room temperature.  Again, all turbidity indicates is the formation of 
light-scattering structures, e.g., the spherical vesicles or similarly-sized structures, but tubule 
formation is certain only when a precipitate has formed and it is microscopically examined for 
the presence of tubules. 
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2.3 Instrumentation and Theory 
2.3.1 Optical Microscopy 
 Differential interference contrast microscopy (DIC) was conducted with a Nikon Diaphot 
300 inverted microscope equipped with 60x and 100x Nomarski objectives.  A small amount of 
the sample was placed on a glass microscope slide, air dried and viewed or covered with a glass 
coverslip and mounted upon the oil-immersion microscope stage for viewing. 
2.3.2 Theory of Nomarski DIC 
Nomarski DIC is a type of interference microscopy; interference microscopy is generally 
used in samples that have low optical density (i.e., refractive index) changes at interfaces, such 
as at a membrane/solution interface, making these edges difficult to see.1  Interference effects are 
used to enhance the contrast of materials being viewed. 
Interference occurs when a single optical beam is split and the two beams recombine after 
traveling along paths of optical lengths that differ by any length not happening to be an integral 
multiple of the light’s wavelength.  This path difference can be “real” – that is, physical distance, 
or a consequence of the two beams encountering media of different indices of refraction.  
In the practice of interference microscopy, a doubly-refractive crystal plate underneath 
the sample specimen splits the beam into two spatially-resolved beams that differ in phase, 
typically ¼ a wavelength.1  Typically these beams are recombined just before the eyepiece, with 
an additional ¼ wavelength retardation introduced.  Combining two beams differing by ½ 
wavelength should of course result in cancellation, i.e., a dark field of view.  But, variations of 
the specimen’s index of refraction contained within its structure, introduces additional phase 
differences between the two spatially-resolved beams.  That is, in any part of the sample in 
which neighboring regions vary in refractive index, the two beams are slowed down or refracted 
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by different amounts (light travels slower in areas with a higher refractive index).  When these 
two beams are reunited after exiting the specimen, differences in brightness occur that 
correspond to the differences in refractive index (or thickness) of the sample can now be seen, 
except for the (highly unlikely) possibility that the sample has introduced exactly ½ wavelength 
between the two beams. 
The splitting and recombination of light beams is usually done in two ways: 1) by using 
reflective surfaces; or 2) birefringent crystals.2  In the first, the light can take two different paths 
by reflection from a series of reflecting surfaces, and the second, the light is split into two beams 
and recombined by using birefringent crystals (as in the case of Nomarski DIC).       
Similar to phase contrast microscopy, interference microscopy allows viewing of 
otherwise transparent objects having even slightly different indices of refraction.2  This is 
accomplished by translating the phase changes in light traveling through the specimen’s different 
optical densities into changes of amplitude of the recombined wave.  In phase contrast 
microscopy, the contrast enhancement is attained by a single beam of light, and the diffraction is 
caused by the sample in order to produce destructive or constructive interference.  In interference 
microscopy, the image is obtained from two beams of light passing separately through the 
sample in different regions with different refractive indexes.  
Nomarski DIC was developed in the 1950s.  It is distinguished by a noticeable relief 
effect giving a three-dimensional appearance, and shallow field depth.  The characteristic three-
dimensional image appears due to the shearing effect of the Nomarski prisms (see Figure 2.2 for 
DIC light path).  Light first passes through a polarizer, which selects light whose electric field is 
aligned along a particular direction.  This plane polarized light passes through a Nomarski 
modified Wollaston prism that is positioned 45o with respect to the polarized light beam.  The 
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prism consists of two quartz wedges that are cemented together along their hypotenuse.  The 
shear takes place at the quartz-air interface of the lower prism.  Refraction at this interface causes 
the sheared wave fronts to converge outside the prism.  (In the Wollaston prism, shear takes 
place at the cement boundary.)  The 45o prism orientation splits the incident plane-polarized 
beam into two perpendicular, equal constituents.  As the components travel through the 
condenser, they exit parallel to each other and continue through the sample specimen and 
objective.  A second Nomarski modified Wollaston prism located behind the objective causes the 
recombination of the two constituents.  The analyzer assembles the vibrational directions parallel 
in order for the light rays to interfere at the intermediate image plane.   
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Objective back
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Figure 2.2  Nomarski differential interference contrast microscopy; showing light path 
(adapted from McCrone). 
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2.3.3 Atomic Force Microscopy (AFM) 
 Contact-mode atomic force microscopy (AFM) probes of samples were obtained with a 
Digital Instruments BioScope, equipped with silicon nitride NanoProbe SPM tips.  The sample 
was prepared in the same fashion as the optical microscopy samples, air dried on a glass slide.  
Images shown are representative of the entire sample.  After acquiring the images, an image 
flatten method was performed.  In the micrographs shown the brightest regions of the scan are 
the tallest features.      
2.3.4 Theory of AFM 
 The atomic force microscope, also referred to as, scanning probe microscope, was 
developed by G. Binnig, et al. in 1986.3,4  AFM gives significant information about surface 
features.  AFM images are created by measuring the interaction of forces between the tip, which 
is attached to the end of a cantilever, and the surface.  As the cantilever is scanned across a 
surface by a piezoelectric tube, the z-axis, or vertical component, is measured in order to gain 
information about differences in height.5  This difference in height is recorded as the laser beam 
that is positioned on the cantilever is reflected onto a photodiode (see schematic in Figure 2.3).  
The height is calculated from the z displacement of the cantilever and the spring constant of the 
cantilever.  
In this dissertation, contact mode AFM was employed.  In this mode, the tip is brought in 
contact with the surface and the cantilever deflection remains steady throughout scanning.6  This 
is done by using a feedback loop, where a constant force is maintained between the cantilever 
and the specimen by moving the scanner vertically, so the force between the tip and the 
specimen remains balanced.  This vertical distance is then measured by the photodiode.    
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Figure 2.3  Schematic of atomic force microscopy. 
 
2.3.5 Scanning Electron Microscopy (SEM) 
 A drop of the sample was placed upon a conductive carbon substrate (12mm diameter 
Carbon Adhesive Tabs from Electron Microscopy Sciences) on top of an aluminum stub and air 
dried.  The air dried samples were then sputter coated with a gold/palladium mixture under 
vacuum in an Edwards S150 sputter coater before viewing.  The specimen was examined on a 
Cambridge Steroscan 260 Scanning Electron microscope. 
2.3.6 Theory of SEM 
 Scanning electron microscopy was developed in the early 1950s.  It uses electrons, 
instead of light (in the case of optical microscopy), to create an image, and it provides a greater 
depth of focus as a result.7  It also is able to create 3-dimensional images, unlike optical 
microscopy and transmission electron microscopy.  SEM has an electron gun at the top of the 
microscope that produces an electron beam, usually a Tungsten hairpin filament.  This filament 
is a loop of Tungsten that functions as a cathode as it releases electrons towards the anode when 
sufficient electrical bias is supplied.  The electron beam travels vertically down the column of the 
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microscope as it passes through an anode, which speeds up the electrons, and a series of 
electromagnetic lenses that focus and define the beam as it approaches the sample.  When the 
electrons hit the sample, backscattered and secondary electrons are produced.  Backscattered 
electrons are a result of the electron beam interacting with the nucleus of the atom.  These 
electrons will circle the nucleus, where they pick up speed due to the positive charge in the 
nucleus, and head back out of the sample.  These electrons are collected in a detector.  Secondary 
electrons, on the other hand, are produced as a result of the electron beam interacting with 
electrons in the atom.  Since the electrons in the atom have a negative charge, the electrons that 
have entered the specimen are slowed down as it repels the specimen electrons.  The electrons in 
the specimen are forced out of the atom and exit the sample.  Since they are moving slowly, the 
detector collecting secondary electrons must have a positive charge.  The detectors collect both 
backscattered and secondary electrons and translate them into a signal that can be viewed as an 
image.   
2.3.7 Energy Dispersive Spectroscopy (EDS) 
 A drop of the sample was placed on a copper planchette and air dried.  The sample was 
them viewed with a JEOL 2010 High-resolution Transmission Electron Microscope (HRTEM) 
attached with an EDAX EDS x-ray analysis for composition analysis. 
2.3.8 Theory of EDS 
Energy dispersive spectroscopy is a non-destructive analytical tool.  It is able to give 
quantitative composition information without the introduction of standards into the specimen 
because x-ray fluorescence wavelengths and fluorescence yields from the calibrated electron 
beam are well-known.8  EDS allows scans as small as 0.5 microns in size and has minimum 
detection limits varying from 0.1 weight % to a few weight %.    Elements with atomic numbers 
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ranging from Boron (Z=5) to Uranium (Z=92) can be detected using this technique.  When an 
electron beam interacts with the sample, if the electrons are of sufficiently high energy to ionize 
are at least promote an atom’s K electron to an L, M, N edge, or and L electron to an M, N, edge, 
and so forth, x-rays are produced as the higher-shell electrons cascade down towards the 
vacancy. The x-rays are collected by a high-resolution detector, usually a SiLi crystal (a Silicon 
crystal doped with small amounts of Lithium).  X-rays that are emitted from the sample atoms 
are characteristic in energy and hence wavelength to the element of that atom and also give 
information on which shells lost electrons and which shell has replaced them.   
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Chapter 3 
A New Tubule Formation Intermediate: The Tubelet* 
3.1 Introduction 
Optical microscopy presents some powerful advantages:  1) temperature control is easily 
done; 2) the specimen need not be desiccated; and, 3) the microscope observation can be 
videotaped, enabling “real-time” studies of tubule formation.  But, tubule sizes are not ideal for 
optical microscopy studies.  Even with a 100× objective and a 10× eyepiece, the highest power 
elements available, the tubules’ helical substructure is generally very difficult to resolve.  Also, 
at these high magnifications, the focal plane (i.e., depth of view) is very narrow (≈0.1 µm), 
making observation of the whole tubule difficult.  Because optical microscopy, as practiced here, 
is a transmission-mode probe, the specimen must be sufficiently transparent, e.g., thin enough for 
light to be transmitted through it; and in our particular case, the tubule suspension must be 
sufficiently dilute so that isolated tubules can be observed.  So, while optical microscopy has 
provided some of our most dramatic observations – most especially “real-time” tubule formation 
-- optical microscopy was in fact generally limited to confirming the presence of tubules and 
cones in DC(8,9)PC/lysozyme mixtures in specimens destined for AFM or electron microscopy 
study, because the features of interest require these higher magnifications to characterize. 
We are going to focus our attention now on the protein-containing specimens described 
in section 1.2.2.1 As droplets of the protein-containing suspension deposited on electron 
microscopy carbon substrates air dried over a period of a few hours, a waxy deposition bed 
formed as the saturated solution containing the tubules evaporated.2  Upon further drying, this  
_______________________________ 
*Portions of this Chapter were reprinted with permission from Journal of the American 
Chemical Society, Copyright (2005) American Chemical Society. 
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waxy deposition bed cracked, forming a pattern reminiscent of a desiccated lakebed.  We 
surmise that the mixture of tubules, cones, tubelet ribbons and protein (undoubtedly a random 
coil at our ethanol concentrations) initially form a gel, which, as drying continues, fractures, 
creating the surface seen in Figure 3.1.  Under identical conditions, protein-free specimens, 
which are known to be free of cones and ribbons, stay completely smooth and do not crack upon 
drying.  
 
 
 
 
 
 
 
 
 
 
Figure 3.1  A low-magnification scanning electron micrograph of an air-dried deposition 
bed of DC(8,9)PC-lysozyme specimen subjected  to the tubule/cone formation process, 
showing extensive cracking of the deposition bed.  The scale bar is 2mm.  Reprinted with 
permission from reference 2, Copyright (2005) American Chemical Society.   
 
The vertical surfaces exposed in these cracks are, in many ways, similar to those revealed 
by freeze-fracture processes, except that this process is gentler, and because the exposed crack 
faces are vertical (or nearly so), they present the great benefit of conserving orientational 
information with respect to the bulk specimen.  That is, the interior exposed by this process is not 
randomly selected, as it would be with conventional freeze-fracture techniques, but rather, it 
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allows us to examine assembly products as a function of depth from the deposition bed surface.  
This remarkable, wholly unexpected behavior enables examination, in detail, far greater than 
conventional freeze-fracture allows, a previously-unknown structure that we call the “tubelet”.  
The extent of detail that can be observed is seen clearly in Figure 3.2, in which tubelets are seen 
to extend from the deposition bed into free space, freeing the object from interfering background, 
e.g., overlapping nearby structures and dried bulk solution.  Since the object projects into space, 
the electron microscopy stage can be rotated and/or translated in order to obtain very high-
contrast images from a single tubelet from several viewpoints. 
 
 
 
 
 
 
 
 
 
Figure 3.2  Scanning electron micrograph of a protein-bearing deposition bed crack 
discontinuity.  Cones are evident on the unbroken bed face, but tubelets are only resolvable 
when they emerge at the crack discontinuity.  Reprinted with permission from reference 2, 
Copyright (2005) American Chemical Society.   
 
 
Figure 3.2 shows tubelets to be structures similar to a flattened fire hose that can twist 
about its long axis, wind helically about this axis, or remain flattened.  The topological 
differences between a phospholipid bilayer ribbon and the nearly edge-free tubelet are 
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immediately recognizable:  The “fire hose” tubelet structure addresses the solvation energetics 
problems that exist with the flat bilayer ribbon by virtue of nearly eliminating ribbon edge-
associated energy costs, except of course, at the flattened tubes’ ends.  (Of course, the membrane 
bending energy at the flattened ribbon’s edges cannot be ignored, but as will be discussed later, 
these sharply-curved features may be a consequence of membrane chiralization, and actually 
represent a lower energy state than the unflattened cylinder.)  Tubelet structure also explains the 
conservation of interlamellar spacing observed over a wide range of tubule compositions and 
diameters - - no matter how you twist or wind a tubelet, its intrinsic interlamellar spacing will be 
detected by x-ray diffraction.1,3,4  Indeed, SAXS and AFM results show that without exception 
tubule walls have thicknesses that are multiples of two DC(8,9)PC bilayers, which is most easily 
interpreted as a consequence of tubelet structure, as suggested in Figure 3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3  Cross-section of proposed tubelet structure.  Note that it has a height of two 
bilayers, twice that of a simple bilayer.  For clarity, each tail drawn actually represents two 
tails of the phospholipid. 
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Renditions of 3-dimensional objects in two dimensions can lead to gross exaggerations, 
e.g. “flat” representations of the earth all contain significant distortions.  In this way, this Figure 
3.3 dramatically over-emphasizes the packing defects that must occur at the tubelet’s edges; we 
expect that molecules in the vicinities of the creases would tilt out of the plane and fill this space 
effectively.  The principal idea of Figure 3.3 is to show the repeating vertical distance – created 
by the phospholipid multilayer – that would be consistent whether this fundamental building 
block were wound, twisted or remained flat. 
 3.2 Deposition Bed  
 Examination of the dried deposition bed shows it to be vertically stratified with ribbon-
like structures appearing out of the crack face at some depth from the surface (~1 µm), seen in 
Figure 3.4.  The lysozyme/tubule mixture forms an entangled fluid network whose structure is a 
consequence of gravity, electrostatic charge, and surface tension, and we surmise the cracking 
process that exposed the deposition bulk interior was gentle enough to not disturb this 
stratification.  That is, the solvent evaporates slowly, causing the sample to form a gel, locking 
these components at their equilibrium electrostatic positions.  As the evaporation continues, the 
gel steadily desiccates, decreasing the volume of the deposition bed and forming deep cracks 
perpendicular to the surface.  The ribbons are usually pulled ~ 20 µm from the crack before 
breaking.  It is apparent from the length and alignment of the ribbon-like structures that the 
contraction and splitting of the bed is a gentle process.  These observations are coherent with 
accounts of sol-gel processes where the stratification is distinguished by electrostatic charge 
separation energy minimization.5  Our studies suggest that stratification places tubules and cones 
only at the air/liquid surface of the deposition bed; they are not found at any distance away from 
the surface.   
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Figure 3.4  Scanning electron micrograph “edge-on” view of a DC(8,9)PC-lysozyme 
deposition bed crack, showing stratification and broken ribbon-like structures projecting 
into free space.  Reprinted with permission from reference 2, Copyright (2005) American 
Chemical Society.   
 
 
Since tubules and cones appear to be restricted to the bed surface, and tubelets are only 
observed within the deposition bed, surface characterization techniques such as SEM and AFM 
are unable to detect these tubelets under normal conditions.  Tubelets also can not be 
distinguished by TEM; at the lipid concentrations required for these studies (and those resulting 
from air-drying required for TEM) tubelets simply cannot be differentiated in the tangled mass of 
self-assembled structures composing the gel.  On rare occasion a flat, untwisted tubelet is located 
at the air/deposition cake surface and can be seen by surface probes, but until now, such 
structures were interpreted as partially submerged tubules.  For these reasons, the tubelet, which 
we interpret to be the principal tubule and cone precursor, remained unobserved until these 
experiments were conducted.  
3.3 Tubelets 
We emphasize that the contrast between vacuum and the crack surface allow highly 
detailed examination of the deposition bed structure normal to the substrate surface, and 
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especially of tubelets projecting from the crack.  Tubelets usually extend ~ 20 microns from the 
crack, but there are regions ranging from sub micrometer lengths to tubelets that emerge from 
one crack face, extend for over 100 µm until reentering the opposite crack face.  Tubelets within 
a region are approximately the same length due to the environment within that region.   
The cracks are not of uniform width along their length, and presumably did not widen at 
a uniform rate (or even time) throughout the deposition cake.  Areas are observed where crack 
separation occurred rapidly, leaving only short tubelets projecting from the crack face, while in 
other areas, 100 µm long tubules are seen to emerge from one crack face and enter the opposing 
face; it is possible that such cracks widen slowly enough for “slippage” to occur as the tubule 
emerged from the drying gel. 
It is difficult to determine tubelet total length, since at least one tubelet end is buried in 
the deposition bed.  Tubelets entering the deposition bed close to the surface can be observed up 
to 30 µm in length using SEM before the tubelet becomes hidden.  This gives a total observation 
length of approximately 50 µm and is consistent with the tubelets lengths on the order of 100 
microns, which is expected for tubule formation.   
 Tubelets are always flattened in a (1) cylindrically wound state, type “A” curvature 
(termed by Oda et al.),6 (2) axially twisted state, type “B” curvature, or an (3) untwisted, 
unwound state, although these are rarely seen, at least under our observation conditions. 
 3.3.1 Cylindrically Wound Tubelets 
Although type “B” tubelets prevail, cylindrically wound type “A” tubelets are also 
observed winding like that of a ribbon to form a cylindrical structure seen in Figure 3.5.  This 
type “A” formation is a precursor to tubule formation.   
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3.3.2 Axially Twisted Tubelets 
The axially twisted tubelets, type “B”, wind about the long axis of the fine structure 
shown in Figure 3.5.  Under these conditions, this type “B” structure is most often seen.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5  Scanning electron micrograph view of a crack face discontinuity from which 
structures possessing types of “A” and “B” windings are seen to project.  Reprinted with 
permission from reference 2, Copyright (2005) American Chemical Society.   
 
 
3.3.3 Flat Tubelets 
Both wound and twisted tubelets have flat regions where they emerge from the crack, this 
may be due to the stretching that occurs when the material dries and the crack faces separate.  
Although very rare, there are areas where flat tubelets can be observed.  Flat tubelets are often 
found in groups, as in Figure 3.6, which suggests the consistency of formation conditions at the 
time of separation (it is possible that the tubelets had not yet chiralized at the time of crack 
separation).  
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Figure 3.6  Scanning electron micrograph of unwound tubelets at a narrow crack interface.  
Reprinted with permission from reference 2, Copyright (2005) American Chemical Society.   
 
 
3.3.4 Other Regions 
Transitions between axial, cylindrical, and flat regions are frequently detected, as seen in 
Figure 3.7.  The winding or twisting can change at flat/“A”, flat/“B”, or “A”/“B” connections.  
Another transition can be seen in Figure 3.7, where there is a kink in “B”/“B” and it is possible at 
these kinks for the twisting pattern to reverse.  The cylindrical curvature and axially twisted 
phenomenon mentioned above has been observed in an unrelated gemini surfactant system.6  
(The cylindrical curvature is seen to form helical ribbons, while the twisted tubelets exhibit 
“Gaussian” curvature.)  By studying charged gemini surfactants, the determination was made 
that long chain surfactants favor helical ribbons while short-chain surfactants favor twisted 
ribbons.  The authors also developed a theory that for membranes in a fluid phase, a twisted 
ribbon has the lowest free energy, and that crystalline order is not compatible with this Gaussian 
curvature,7 and that a helically-wound ribbon must be stabilized by crystalline order.  Therefore, 
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they believe that twisted ribbons and helical ribbons result from fluid membranes and crystalline 
membranes, respectively.   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7  Scanning electron micrographs.  (Top): A tubelet that emerges from a crack 
face with a right-handed type "B" winding, changes to flat configuration at its center, and 
resumes a right-handed type "B" winding before emerging at the opposing crack face 
discontinuity, (Bottom): A tubelet that undergoes a continuous transition from a type "A" 
winding at its left, to a type "B" winding at its center, and finally to a flat state as it enters 
the crack discontinuity.  Both scale bars are 10 µm.  Reprinted with permission from 
reference 2, Copyright (2005) American Chemical Society.   
 
 
3.4 Tubelets as a Precursor 
When tubules were first observed, deGennes suggested that they form as a result of a flat 
bilayer that winds to form tubules because of a ferroelectric charge separation resulting in the 
leading and trailing ribbon edges possessing slight amounts of opposing charge.8  This theory 
was disproven by salt-screening experiments intended to interfere with this self-assembly 
mechanism.9  Close examination of Figure 3.8 shows a topologically much more complicated 
structure - tubelets are not flat, but are actually hollow flattened tubes that wind up to form 
hollow cylindrical tubules.   
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Figure 3.8  Scanning electron micrograph of an axially-twisted (type "B") tubelet, with 
characteristic 3 µm twist periodicity and a 90 degree kink where axial twist handedness 
sometimes, but not always, changes chiral sense.  (This structure's left-handed twist does 
not change chiral sense at this junction.)  (Inset): Magnification of the hollow tubelet's right 
end.  The scale bar is 1 µm.  Reprinted with permission from reference 2, Copyright (2005) 
American Chemical Society.   
 
 
Our observations suggest the process shown in Figure 3.9:  1) A continuous hollow 
bilayer tube, the “tubelet,” forms 2) the tubelet flattens spontaneously into either a cylindrical 
type “A” or axial type “B” curvature, or rarely, with no curvature.  Our findings strongly suggest 
that DC(8,9)PC tubules and DC(8,9)PC/lysozyme cones are a result of the helical winding of 
these previously-unobserved tubelets.  This model explains several of the problematic tubule 
features.   
First, the unfavorable solvation energy along the edges of the ribbon before it winds to 
form a tubule is minimized.  The sharp curvature occurs as a result of the tubelet becoming 
flattened, and membrane chiralization through spontaneous chiral symmetry breaking may play a 
significant role in the formation of creases and flattening of the initial, unflattened tubelets.  
Several papers have discussed the idea that chiral defects must form in adequately large chiral 
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domains.6,10,11  We conjecture that as tubelets grow, increasing in length and perhaps diameter, 
such chiral defects occur and result in the twist (configuration “B”), or helical winding 
(configuration “A”). Our experimental discovery suggests profound re-evaluation of the ribbon 
edge/tubelet crease contributions to tubule energetics be undertaken.  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9  The formation of type "B" and "A" curvature structures appears to begin with 
the formation of the cylindrical tubelet (left), which spontaneously flattens (center).  The 
tubelet occasionally remains flattened but far more likely assumes a type "B" curvature 
conformation (top right) or a cylindrical "A" curvature (bottom right).  The inset drawing 
indicates the bilayer orientation of the amphiphilic molecules.  Reprinted with permission 
from reference 2, Copyright (2005) American Chemical Society.   
 
 
Second, the persistence of the “barber-pole” ridge on the surface of the tubule and the 
stability of propanol/DC(8,9)PC helices12 and phosphonate DC(8,9)PC derivative helices3,4 are 
made clear by this model.  The ridges are not a result of two membranes meeting edge-to-edge 
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and fusing together but occur as two hydrophilic membranes form a junction.  The “open” 
helices found in propanol/DC(8,9)PC and DC(8,9)PC phosphonate derivatives are thus seen to 
present hydrophilic headgroups along their edges,  instead of exposed hydrocarbon tails under 
earlier tubule structure models.   
 A third tubule feature problem that is addressed by the discovery of tubelets is the tightly 
conserved interlamellar spacing found in tubules of different dimensions, compositions, and 
symmetry.  SAXS and AFM show that phosphonate and DC(8,9)PC tubule walls are either two 
or four bilayers thick – odd number of bilayers are never observed.  This is sensible if the bilayer 
“ribbon” is actually a collapsed bilayer tube.  Using this model, the tubule in Figure 3.5 should 
have a wall thickness of two bilayers and the tubule wall thickness can be in increments of two 
bilayers, consistent with the SAXS and AFM determinations. 
Are tubelets generated as a result of the introduction of protein into the system and not 
related to the formation of tubules?   That is, does the protein deform existing cylindrical tubules 
into helically-wound tubelets?  While the look and dimensions of the type “A” helical winding 
tubelet seen in Figure 3.5 and the bottom of Figure 3.7 provide a strong case for tubelets being a 
tubule precursor, they have only been detected in specimens containing protein.  Nonetheless, we 
contend that tubelets are indeed tubule predecessors in protein free systems but can not be seen 
by SEM and TEM. 
 SEM and TEM investigation of the smooth regions of specimen containing protein reveal 
the coexistence of cones and tubules (seen in Figure 3.2), but neither technique detects tubelets 
in these uncracked regions.  However, the crack of Figure 3.2 shows tubelets are there in large 
quantity.  It appears SEM is unsuccessful in finding tubelets in the smooth regions because they 
are sufficiently far below the deposition bed surface to be detectable.  On the other hand, TEM is 
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unable to resolve tubelets because of the closely packed structures within the ~ 12 µm deposition 
bed depth.  At the protein-bearing specimen’s deposition bed cracks, tubelets are seen in 
remarkable detail over large distances when they project from the crack face because there is no 
background obstruction of the specimen.  These structures can only be found at distances of ~1 
µm below the deposition bed surface.  We believe that tubelets are also present in protein-free 
specimens, but are not detectable because they are within the specimen’s interiors, and protein-
free specimens do not crack to expose the inside of the deposition bed.  If protein-free systems 
would form cracks, the beds’ internal organization and intricate structures could be compared.  
Vertical slices made into these specimens with a razor blade do not reveal tubelet structures, 
however, the enormous artifacts that slicing makes in the sample, renders them completely 
uninterpretable.  Extended efforts using conventional freeze-fracture techniques also failed to 
reveal these structures, in part because of the loss of orientational information, but largely due to 
the very limited sizes of regions that freeze-fracture would expose.  
 There similarities of cone and tubule structure seen not only in optical video microscopy 
but in SEM and SAXS studies of their internal structures strengthen the argument that cylinders 
and cones are more alike than dissimilar.  The helical ridges on the both structures’ exteriors, the 
remarkable conservation of interlamellar spacing, and the tubule wall thicknesses (always 
consisting of multiples of two bilayers) suggest strongly that tubule and cones are different 
manifestations of the tubelet precursor. 
3.5 Conclusions 
 The interactions of gravity, electrostatic charge, and surface tension cause the structure of 
entangled protein-fortified fluid matrix to gel, crack, and expose the interior structure of the bulk 
droplet, revealing a previously-unobserved structure, the “tubelet”.  These tubelets appear to be 
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tubule precursors in protein-free systems and of tubules and cones in systems containing protein. 
The tubelet-as-precursor structure explains several important tubule characteristics and may 
signify a major shift in our understanding of their structure and how they form.  The possibility 
of using tubules in applications such as biomedical encapsulation should be reassessed as well: 
rather than offering a simple 0.5 µm cylinder, from which encapsulated drugs would be expected 
to diffuse from so rapidly as to make the encapsulation pointless, tubules should now be regarded 
as a secondary winding of a smaller tube that may provide longer encapsulant retention times 
that are significantly longer than what would be expected from a simple hollow cylinder.  
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Chapter 4 
Encapsulation Studies with Chemotherapy Agents 
4.1 Introduction 
 To determine whether or not tubules can be used as vehicles for medicines, it is first 
necessary to see whether or not they can even form in the presence of the drugs. This can be 
done in a straightforward fashion by optical microscopy, atomic force microscopy (AFM), and 
scanning electron microscopy (SEM).  These probes will also allow us to see if structure of the 
tubule is the changed by the drugs. 
If tubule formation persists in the presence of drugs, it must be in at least one of three 
places.  The drug can stay in the bulk of solution, in the solution contained in the hollow tubule 
or tubelet composing the tubule, or become integrated into the tubule membrane.  So long as 
either possibility (2) or (3) occurs, water-soluble and water-insoluble drugs can be considered for 
encapsulation:  Water-soluble drugs will be encapsulated in the solution within the tubelet, or 
inside the larger tubule cavity, while water-insoluble drugs will partition within the membrane, 
i.e., with the hydrophobic tails of the phospholipid.  AFM experiments will determine the effects 
that the drug has on tubule morphology, while energy dispersive spectroscopy (EDS EDAX) can 
help determine the location of the drug. 
 Tubule dimensions allow them to be aerosolized.1  This property, along with the 
presumed biocompatibility of phospholipids with tissue membranes, suggests strongly that 
tubules can serve as benign drug carriers and be used in aerosol therapies.  Aerosol therapy has 
two evident applications: medicines can be inhaled for application to respiratory tract tissue for 
treatment of asthma, epithelial cancer, or other illnesses of the lung.  Interestingly, control of 
tubule diameter alone would permit regulation of their effective aerodynamic diameter, which in 
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turn would permit drug delivery to a specified distance along the respiratory tract.2  Medicines 
can also be introduced into the circulatory system by inhalation for target sites outside of the 
lung.  This delivery mode may enhance the efficacy of the medicine, for blood from the lungs is 
dispersed throughout the body before passing through the liver, where many drugs are processed 
for excretion.  Not only could it enhance the efficacy, it could provide an alternative route for 
drug delivery of chemotherapy agents, which are currently administered intravenously.  As 
cancer research is of very high interest, this can open many doors for these types of drugs. 
 Chemotherapy drugs are used to kill rapidly growing cancer cells.  But, these drugs also 
kill healthy, rapidly growing cells such as stomach lining cells, red blood cells, platelets, and 
white blood cells.  Being able to deliver the drug in a fashion that would minimize exposure to 
those tissues while targeting the cancer cells could prove more beneficial to treatment, as well as 
minimize the side effects.  Although most chemotherapy drugs are delivered though an IV, some 
forms of chemo are delivered orally.  If tubules can be used to encapsulate chemotherapy drugs, 
it may be possible to deliver these drugs though an inhaler.   This could be a useful way to 
deliver any chemotherapy drug, if an adequate quantity can be delivered to the body.  For the 
specific application of lung cancer, however, massive doses of the toxic drug can be delivered 
locally to the cancerous lesions, and because the dose is delivered to the desired point of action, 
the dose to the body overall can be quite small, sparing the stomach lining, blood cells, etc.  By 
changing tubule diameter, we can manipulate the effective aerodynamic diameter of the tubule 
allowing us to determine which part of the lung the drug filled tubule would travel.2  The larger 
the tubule diameter, the larger the aerodynamic radius, and the further down the bronchial tubes 
the tubule will travel.  In this way, concentrating the toxic chemotherapeutic agents at the desired 
point can permit larger doses at the cancerous site and lower doses to the body in toto.   
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 Another potential medical use does not involve aerosolization, but rather, direct 
implantation into the body, e.g., via subcutaneous injection.  The anticipated advantage of this 
technique would be the slow release of encapsulated drugs directly “upstream” from the tumor, 
inflamed joint, etc., from which the tubules have been implanted.  The slow, “point” source 
release could potentially deliver would be particularly promising for a number of the drugs.  One 
should also consider that this “point” specificity may not matter for some drugs, but that tubules’ 
potential long release time could nevertheless provide a substantial benefit, e.g., the continuous 
release of growth hormone over a period of weeks or even months.  
4.2 Methotrexate Studies 
 Methotrexate (MTX), N-[4-[[(2,4-diamino-6-pteridinyl)methyl]-methylamino]benzoyl]-
L-glutamic acid, whose chemical structure is shown in Figure 4.1, is used as a treatment for 
breast and lung cancers and autoimmune diseases, such as Crohn’s disease and rheumatoid 
arthritis.3  MTX is an antimetabolite; it is similar enough in structure to participate in normal 
biochemical reactions but different enough to interfere with normal division and function of 
cells.  This is due to the fact that MTX is a folic acid analogue.4,5  In 1947, aminopterin was 
synthesized by changing the 4-oxo moiety of folic acid to 4-NH2.6  This slight change in the folic 
acid caused the vitamin to become very toxic by the body’s inability to differentiate it from the 
essential folic acid.  It was used successfully in childhood leukemia but its toxicity inspired 
development of its 10-methyl congener, MTX, in the 1950s.5   Since it also is a folic acid 
analogue, it is able to inhibit enzymatic pathways for biosynthesis of nucleic acids by 
substituting for folic acid.  This inhibition interferes with the production and maintenance of 
DNA, allowing MTX to be used as a chemotherapy agent.7  It is a yellow fluid that can be 
administered intravenously, through a central line, or into a PICC line or given as an IV drip.3  It 
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can also be injected into the muscle, artery, or fluid surrounding the spinal cord.  It can also be 
administered orally, if taken with plenty of water.   The side effects include loss of blood cells, 
diarrhea, tiredness, sore mouth and taste change, skin changes, inflammation of the cornea, 
blurred vision, hair loss, sensitivity to sun, changes to lung tissue, and kidney and liver damage.3  
Delivery of this potent drug to the desired point of action could minimize these serious side 
effects.  
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Figure 4.1  Chemical structure of methotrexate. 
A sample was prepared by adding methotrexate to the standard 1 mg lipid / ml stock 
solution, where the percentage of drug in the sample was very high, 28 weight%.  The sample 
was subjected to the canonical DC(8,9)PC tubule formation process, that is, heating to 45oC, 
where, as with pure DC(8,9)PC specimens, the solution became clear.  The sample was then 
allowed to cool slowly back to room temperature where it became a cloudy yellow solution, 
indicating that tubules had formed.  Optical microscopy was performed in order to confirm the 
presence of tubules.  At this very high drug concentration, the number of tubules seen is 
significantly lower than in the pure DC(8,9)PC sample, but it was somewhat surprising to find 
that tubules form at all at such high MTX concentrations.  Some new features are introduced in 
this specimen, shown in the AFM shown in Figure 4.2.  The image shows some branch-like 
structures (resembling crystallization) and some very high structures that look like clumps 
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(possibly the drug's effect on the lipid, or the drug itself) around the tubules that have not been 
observed previously.  Control experiments performed with MTX do not exhibit these features 
either; the AFM scans of MTX under the same conditions (in ethanol/water solution and taken 
through the thermal cycle), remain featureless.  These tall structures make AFM difficult because 
their height exceeds the ≈ 6 µm height maximum of the AFM, compromising several of the 
raster scan lines during the AFM scan.   
 
     Tubules 
 
 
 
 
 
 
 
 
Figure 4.2  100 µm x 100 µm contact mode atomic force micrograph of DC(8,9)PC doped 
with 28% methotrexate.  
 
It is possible, however to take a closer look at a clean area – one free of these tall 
structures -- once the large-area scan has been captured by using the zoom feature when working 
up data.  Such an area is shown in Figure 4.3.   
Given the positive outcome of tubule formation at this high MTX concentration, other 
samples were made at lower MTX concentrations to see if the drug’s influence – apparent 
changes in tubule structure and possible MTX co-precipitation - will continue at these lower 
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MTX concentrations. Methotrexate was added to the lipid stock solution where the percentage of 
drug was 8%.  The sample was taken through the normal tubule formation process and once 
again showed the presence of tubules by optical microscopy.  The AFM of Figure 4.4 shows that 
tubules are much more plentiful as expected due to the higher relative lipid concentration, but 
still not as numerous as in pure DC(8,9)PC samples.  Their diameter is larger in comparison to 
that of MTX-free DC(8,9)PC tubules’ 0.5 µm diameter, indicating a significant interaction 
between the drug and lipid has occurred.  A closer look at the scan reveals that tubule diameter 
has increased to about 1.25 µm, seen in Figure 4.5. One possibility is that the drug is filling the 
inside of the tubule causing it to swell, thus increasing the diameter.  Another possibility is that 
the MTX/lipid membrane interaction has reduced the membrane’s intrinsic curvature, resulting 
in larger-diameter structures.  Further studies must be performed to determine the location of 
methotrexate in the samples and the modified membrane’s bending moduli. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3  50 µm x 50 µm contact mode atomic force micrograph of DC(8,9)PC doped with 
28% methotrexate. 
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Figure 4.4  100 µm x 100 µm contact mode atomic force micrographs of A. DC(8,9)PC 
tubules (shown for comparison) and B. DC(8,9)PC tubules doped with 8% methotrexate. 
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Figure 4.5  10 µm x 10 µm contact mode atomic force micrographs of A. DC(8,9)PC tubules 
(shown for comparison and B. DC(8,9)PC tubules doped with 8% methotrexate. 
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4.3 Mitoxantrone Studies 
 Mitoxantrone, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-
anthracenedione dihydrochloride, shown in Figure 4.6, is another chemotherapy agent used 
primarily to treat breast cancer, myeloid leukemia, and non-Hodgkin lymphoma.8  It is also used 
for treatment of multiple sclerosis (MS).8  It can not cure MS, but it can lengthen the time 
between relapses.  Mitoxantrone is an antineoplastic or “antitumor antibiotic”, which is able to 
interfere with the growth of cancer cells by blocking an enzyme, topoisomerase II, which is 
required for cell division.9,10  When this enzyme is blocked, cells are unable to divide and grow 
into new cells.  Antineoplastics also generate free radicals that damage DNA and cell 
membranes.  Mitoxantrone is a dark blue fluid that can be injected into the vein for 5 to 20 
minutes a day for 3 consecutive days or once every 3 weeks.8  Some of the side effects include 
changes in liver function, sore mouth, reduction in platelet production leading to bruising or 
bleeding, anemia, nausea, and weakness.8   
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Figure 4.6  Chemical structure of mitoxantrone. 
 A sample was prepared using mitoxantrone at the very high concentration of 28 weight%.   
Mitoxantrone was added to the previously-prepared lipid stock solution and heating to 50 oC, 
where the solution was a clear dark blue.  As the solution cooled back down to room 
temperature, it was hard to determine if a precipitate had formed due to the darkness of the 
solution.  Optical microscopy and AFM were conducted on the sample, and because tubules were 
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hard to locate, we conclude that the high concentration of mitoxantrone inhibited, but did not 
completely prevent tubule formation.  Some tubules were present, as seen in Figure 4.7.  
  
 
 
 
 
 
 
 
Figure 4.7  100 µm x 100 µm contact mode atomic force micrograph of DC(8,9)PC doped 
with 28% mitoxantrone. 
  
When the concentration of mitoxantrone was reduced to 8%, tubules were, as with MTX, 
much more numerous, but again, their number is still not quite as large as that of pure 
DC(8,9)PC stock solution run through the thermal cycle without addition of mitoxantrone.  
Again, as in the methotrexate sample seen in Figure 4.2, there is a presence of high structures 
that interfere with the scan.  This again, could be the result of the presence of drug in the sample.  
Even though, the drug is added at 8%, much lower than the original sample with 28%, it 
obviously has an effect on tubule morphology.  Tubules can definitely form after being doped 
with mitoxantrone, but their morphology is altered and the number of tubules is significantly 
lower, as seen in Figure 4.8.  A closer look at the tubules formed indicates that their morphology 
has been altered to yield tubules of much larger diameters, as seen in the isolated tubule of 
Figure 4.9, showing the dramatic increase in tubule diameter from 0.5 µm to 2.5 µm.   
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Figure 4.8  100 µm x 100 µm atomic force micrographs of A. DC(8,9)PC tubules (shown for 
comparison) and B. DC(8,9)PC tubules doped with 8% mitoxantrone. 
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Figure 4.9  10 µm x 10 µm atomic force micrographs of A. DC(8,9)PC tubules (shown for 
comparison) and B. DC(8,9)PC tubules doped with 8% mitoxantrone. 
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4.4 Carboplatin Studies  
 Carboplatin [cis-diamine (1, 1-cyclobutane-dicarboxylato) platinum (II)], shown in 
Figure 4.10, is another chemotherapy drug that is used to treat a wide variety of cancers, 
including ovarian and lung cancer.11  Platinum-containing compounds are often used as 
chemotherapy agents.12-14  Carboplatin was derived from cisplatin, which was discovered in the 
1970s for the treatment of cancer, in an attempt to reduce toxicity.15,16  It is an alkylating agent, 
as it transfers alkyl groups to other molecules, and stops tumor growth by cross-linking guanine 
nucleobases in DNA strands, preventing cell division and leading to eventual cell death.17-19   It 
is a clear fluid that is currently administered as an infusion drip into the vein through a cannula, a 
tube inserted into the vein, or through a central line that is inserted under the skin into a vein near 
the collar bone.11  As with most chemotherapy drugs, the side effects are numerous.  Some of 
these include loss of blood cells, nausea, vomiting, diarrhea, fatigue, loss of appetite and taste, 
changes in hearing, numbness in hands and feet, and loss of hair.11  Carboplatin also has side 
effects that may not occur for months or years after the treatment has been stopped.  Ironically, 
one delayed effect is the induction of another cancer, leukemia.  These side effects can possibly 
be minimized if the drug could be administered in another fashion, via an inhaler, or if the drug 
could be targeted to the site of the cancer via injection, minimizing exposure of the whole body 
to the drug.  
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Figure 4.10  Chemical structure of carboplatin. 
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A sample was prepared by adding carboplatin in to the lipid stock solution, where the 
percentage of drug in the sample was 28 weight%.  The sample was heated to 55 degrees Celsius 
where the solution became clear.  The sample was then allowed to cool slowly back to room 
temperature where it became a cloudy solution, indicating that tubules had formed, which was 
confirmed by optical microscopy.  At this high drug concentration, AFM results were generally 
poor because of the presence of tall structures that had been seen in samples where MTX was 
added.  We tentatively conclude, as control studies with carboplatin under these same conditions 
(in ethanol/water and taken through the thermal cycle) remain relatively featureless, that these 
tall structures are carboplatin/lipid co-precipitate.  There is some evidence of cones in our 
sample; one gently-tapered structure is shown in Figure 4.11.   
 
  
 
  
  
 
 
 
 
 
Figure 4.11  15 µm x 15 µm atomic force micrograph of DC(8,9)PC tubules doped with 
28% carboplatin.  This seems to be cone-shaped. 
 
As with the previous drugs, another sample was again made with carboplatin at a 
concentration of 8%.  As before tubules became much more abundant, and again they had 
significantly larger diameters than tubules made from drug-free DC(8,9)PC stock solution (as 
seen in Figure 4.12).  A smaller scan area (that is, at higher magnification) shows tubules with a 
 61
diameter of approximately 2 µm (see Figure 4.13) much larger of those made from pure 
DC(8,9)PC. 
 
A.                                                                            B. 
 
 
 
  
 
 
 
 
 
Figure 4.12  100 µm x 100 µm contact mode atomic force micrographs of A. DC(8,9)PC 
tubules (shown for comparison) and B. DC(8,9)PC tubules doped with 8% carboplatin. 
 
A.                                                                              B. 
 
 
 
 
 
 
 
 
Figure 4.13  10 µm x 10 µm contact mode atomic force micrographs of A. DC(8,9)PC 
tubules (shown for comparison) and B. DC(8,9)PC tubules doped with 8% carboplatin. 
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Carboplatin presents an unusual study opportunity because it contains the high-Z 
element, platinum.  Platinum’s K, L, and M fluorescence is easily differentiated not only from the 
carbon, hydrogen, oxygen, nitrogen and phosphorus contained by DC(8,9)PC, but from any  
metals such as copper, iron, etc. that might compose the electron microscopy grid the specimen 
lies upon.   That is, carboplatin is intrinsically “labeled” for EDS EDAX probes. 
The second, less carboplatin-rich sample was examined using EDS EDAX where we 
were able to locate the carboplatin in the sample.  Figure 4.14 shows EDAX emanating from the 
tubule; fluorescence yield data indicates that the tubule is 4.5 weight % platinum, a surprisingly 
high value.  This finding is underscored by the fact that Pt was not detected anywhere else on the 
deposited specimen surface except on, or within 0.5 µm of the tubules.  The area on the tubule 
exterior (Figure 4.15), revealed platinum present in concentrations of 24.1 weight %, suggesting 
the carboplatin either adheres to the tubule exterior, or is integrated into the tubule’s membrane.  
Figure 4.16 shows that there was absolutely no detectable platinum on the areas of the substrate 
where tubules were not present.   These results indicate that carboplatin adheres to tubule 
exteriors, or incorporates into the membranes, and does so voraciously.  This result is the most 
promising so far with our encapsulation studies.   It is possible that our interpretation that 
carboplatin adheres to the tubule exterior is an artifact resulting from the fact that the sample is 
air dried before it is examined:  If the tubule dries flat, then it is possible that if the carboplatin 
was captured inside the tubule in solution, it may be released upon drying, producing a high 
concentration near the tubule.  But, spatial resolution with EDAXS can be limited by secondary 
electron scattering within the substrate, and the 0.5 µm distance from the tubule edge where Pt is 
found may be an artifact of this “blossoming.”  Whether carboplatin resides in or on the tubule, it 
is apparent that tubule’s potential utility as encapsulation agents merit further research.   
 63
  
Elemental Analysis: 
CK – 75.9 weight % / 87.8 atomic % 
OK – 10.5 weight % / 9.1 atomic % 
PK – 3.5 weight % / 1.6 atomic % 
CuK – 5.7 weight% / 1.2 atomic % 
PtL – 4.5 weight % / 0.3 atomic % 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14  Energy dispersive spectroscopy results of the tubule itself. 
 
 
 
 
 
 Elemental Analysis: 
CK/OK – 39.2 weight % / 72.0 atomic % 
PK – 15.4 weight % / 14.6 atomic % 
CuK – 21.3 weight% / 9.8 atomic % 
PtL – 24.1 weight % / 3.6 atomic % 
 
 
 
 
 
 
Figure 4.15  Energy dispersive spectroscopy results at the perimeter of the tubule. 
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Elemental Analysis: 
CK – 83.0 weight % / 94.3 atomic % 
OK – 3.3 weight % / 2.8 atomic % 
CuK – 13.7 weight % / 2.9 atomic % 
 
Figure 4.16  Energy dispersive spectroscopy results of the substrate area without tubules 
present.   
 
4.5 Conclusion  
 The encapsulation studies prove that it is possible to form tubules in the presence of a 
drug.  The chemotherapy drugs do, however, have a couple of effects on the tubule morphology.  
First, when chemotherapy agents are added at 28%, tubules are not as plentiful and there seems 
to be an existence of high structures in the AFM scans, which are tentatively interpreted as being 
the drug itself co-precipitating alongside the tubules.  Alternatively, these high drug 
concentrations may interfere with tubules formation, creating regions of non-tubule, drug-
containing “bulk” lipid.  The drugs all increase the diameter of the tubules as well.  This effect 
persists when the drugs are added to attain 8% concentrations.  EDS results show that carboplatin 
is centered around the tubule and apparently no carboplatin at all is left in the solution after 
tubules have formed.  More experiments need to be performed in order to gain a better 
understanding of what is happening when the tubules are drying and becoming flattened (or 
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releasing the carboplatin).  Also further studies need to be examined with methotrexate and 
mitoxantrone to determine where it is located throughout the tubule. 
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Chapter 5 
Optimization of Phospholipid Tubule Morphology 
5.1 Introduction 
It is important to understand the significance of optimizing tubule morphology for drug 
encapsulation applications. Tubule drug-loading capacity presumably scales with tubule size, 
that is, a larger tubule should deliver a larger dose.  Because the amount of drug administered to 
the body is adjusted simply by regulating the number of drug-bearing tubules that are delivered, 
the question of why it is important to control tubule size occurs naturally.  The answer is two-
fold:  1)  The drug release rate and the duration of its release are certain to depend upon tubule 
length and diameter; and 2) In aerosol-delivery respiratory therapy modalities, the deposition 
location in the respiratory tract is almost solely a function of tubule diameter.1 
There are two ways to regulate tubule diameter. The first is to modify the tubule-forming 
molecule, e.g., the doubling of tubule diameter by using phosphonate DC(8,9)PC derivatives 
rather than DC(8,9)PC.2,3  This requires considerable (and expensive) synthetic effort and the 
result is “quantized” in the sense that a given molecule tends to produce tubules of a given, and 
possibly off-optimum diameter and length.  The second approach is to add co-surfactants, or so-
called “spacer” lipids that modify whatever processes lead to membrane chiralization and 
winding, or polymers or proteins that exert similar effects, presumably by similar mechanism(s).4 
This latter approach could prove useful for a number of applications, for tubule diameter is 
presumably continuously adjustable by this approach, and the co-surfactant or polymer could be 
an inexpensive, stable material. Optimizing tubule dimensions for a particular application by the 
addition of co-surfactant or large molecules may result in non-cylindrical morphologies that may 
affect their performance (for better or worse), e.g. the protein lysozyme added to the cooling 
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spherical DC(8,9)PC vesicles produces gently-tapered hollow cones, rather than the cylinders 
formed in protein-free systems.5  Whether or not the conical transformation caused by the large 
lysozyme molecule is desirable remains a question for further study. 
In this chapter, two molecules, semi-saturated DC(8,9)PC analog 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine, (DOPE) and cholesterol, are investigated in order to regulate 
tubule morphology.  
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5.2 DOPE Studies 
The semi-saturated DC(8,9)PC analog 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPE) shown in Figure 5.1 was selected as a co-surfactant for its similarity to DC(8,9)PC and 
its unusual tendency to form inverted hexagonal phases above 10 degrees Celsius.6,7  DOPE was 
added in various weight ratios and taken through the thermal tubule formation process to 
determine if tubule formation persisted in view of DOPE’s ability to form inverted hexagonal 
phases, and if so, what changes might be seen in tubule structure.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1  Structure of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, (DOPE). 
 
 
DOPE was first added to existing 1 mg lipid / ml EtOH/H2O stock solution to obtain a 
1:1 DOPE:DC(8,9)PC weight ratio or 1.2 mole%.  At this very high ratio, tubule formation was 
seen to persist, as seen in Figure 5.2, and tubule diameters increased from 0.5 µm to ~1-2 µm 
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upon this introduction of DOPE.  So, at this concentration, DOPE did not prevent tubule 
formation, and exerted only a small change upon tubule structure.  
 
A.           B. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2  100 µm x 100 µm contact mode atomic force micrograph of A. DC(8,9)PC 
tubules (shown for comparison) and B. DOPE:DC(8,9)PC [1:1] tubules, showing an 
increase in diameter. 
 
Given this somewhat surprising outcome, samples were prepared at a 2:1 
DOPE:DC(8,9)PC weight ratio or 2.5 mole%. Figure 5.3 shows that tubule formation still 
persists at the 2:1 DOPE:DC(8,9)PC weight ratio, but now tubule diameters are found to range 
from 1 µm to 6 µm.  These results are consistent with those of Singh et al.; simpler “spacer 
lipids”, short-chain saturated phospholipids, were used to tune the diameter of DC(8,9)PC 
tubules.4  When chain lengths are long enough, these spacer lipids can penetrate the membrane to 
the depth of the DC(8,9)PC diacetylene groups, thus interfering with diyne/diyne interactions.  
This interference causes an increase in tubule diameter above the otherwise narrowly disperse 
0.5 µm diameter; and DOPE’s chain length is just long enough to “mask” the diacetylene group 
interactions and cause an increase in diameter.  So, in conclusion, the presence of DOPE does 
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not cause a change in phase or a disruption in the lamellar phase out of which tubules form, even 
at preponderant concentrations of 4:1 DOPE:DC(8,9)PC (4.9 mole%).  
 
 
A.             B. 
 
 
 
 
 
 
 
 
 
 
Figure 5.3  100 µm x 100 µm contact mode atomic force micrograph of A. DC(8,9)PC 
tubules (shown for comparison) and B. DOPE:DC(8,9)PC [2:1] tubules, showing an 
increase in diameter. 
      
5.3 Cholesterol Studies 
Cholesterol, shown in Figure 5.4, is a rigid ring system with a short branched 
hydrocarbon tail.  It is largely hydrophobic due to its possessing only one hydrophilic moiety, a 
hydroxyl group.  Even so, the distal position of the hydroxyl group makes this hydrocarbon 
amphipathic.  Cholesterol is known to insert itself into bilayer membranes with the hydroxyl 
group forming a H-bond with the polar headgroups of the phospholipid and the short branched 
hydrocarbon tail aligning with that of the hydrophobic region of the phospholipid hydrocarbon 
tail.8  By inserting itself into the membrane in this fashion, cholesterol is able to decrease the 
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mobility of the phospholipid tails and cause them to expand or straighten, resulting in an increase 
of bilayer thickness.9-11   
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Figure 5.4  Chemical structure of cholesterol 
 
As cholesterol is known to generally increase lipid chain order and bilayer thickness in 
membranes, it was added to the standard  DC(8,9)PC thermal cycling mixture to study its effects 
upon tubule formation, which result from a highly unusual DC(8,9)PC membrane.   
Another reason for choosing cholesterol is that it can serve as an indication of how other 
molecules having the same characteristics might act in the membrane.  If cholesterol can be 
successfully incorporated into the membrane, other steroids such as sex hormones, anti-
inflammatory agents such as prednisone, etc. may act in a similar fashion.  There has been much 
interest in recent years on the delivery of steroid hormones such as estradiol, progesterone, and 
testosterone.  Because these molecules’ structures are derived from cholesterol, cholesterol is an 
excellent model for these other compounds.  
Cholesterol was added to a solution of previously-formed tubules at various mole% ratios 
and taken through the tubule formation thermal cycle, i.e., heating the suspension to clarity and 
cooling slowly.  Surprisingly at 11 mole% cholesterol, no detectable change was seen in tubule 
morphology, as seen in the SEM image Figure 5.5.  Tubule diameter and morphology remained 
unchanged at lower cholesterol concentrations as well.  
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Figure 5.5  Scanning electron micrograph of DC(8,9)PC tubules with 11 mole% cholesterol, 
showing tubule morphology is consistent with that of pure DC(8,9)PC. 
 
When DC(8,9)PC is doped with higher amounts of cholesterol significant changes in the 
morphology can be observed.  Figure 5.6 shows an atomic force micrograph of DC(8,9)PC 
tubules with 40 mole% cholesterol, showing an increase in diameter.  Upon the addition of 30 
and 40 mole% cholesterol, tubule diameter increases because of the addition of cholesterol, as 
shown in Figure 5.7.  The trend discerned is that as the amount of cholesterol increases, so does 
tubule diameter, which is interpreted as the expected increase in bilayer thickness.   
In order to determine whether or not this presumed bilayer thickness was occurring, AFM 
section analysis was performed on the samples.  AFM cross-sections of DC(8,9)PC and 
phosphonates are observed to be trapezoidal and not the expected semi-circular shape that an 
unflattened tubule would generate.2  As the AFM tip is rastered across the sample in a horizontal 
fashion, the vertical displacement is translated as the sample height.  When the tip reaches the 
cylinder’s edge, it is unable to reach under the segment of the cylinder whose portion is tangent 
is normal to the substrate surface.  The section analysis tool can give information on the height of 
the tubules, which can reveal information about the thickness of the bilayers, because it is known  
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A.       B. 
 
 
 
 
 
 
 
 
Figure 5.6  100 µm x 100 µm contact mode atomic force micrograph: A. DC(8,9)PC tubules 
(shown for comparison) and B. DC(8,9)PC tubules with 40 mole% cholesterol, showing a 
change in tubule morphology. 
 
 
A.          B. 
 
 
 
 
 
 
 
 
Figure 5.7  50 µm x 50 µm contact mode atomic force micrograph: A. DC(8,9)PC tubules 
with 30 mole% cholesterol and B. DC(8,9)PC tubules with 40 mole% cholesterol 
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that tubules’ circular cross section flattens upon drying.  A height measurement thereby yields 
information about bilayer thicknesses.  All measurements were made under the same conditions 
in order to make our comparisons as accurate and consistent as possible.  The pure DC(8,9)PC 
height profile, shown in Figure 5.8, reveals that tubule heights are ~100 nm, while 30 mole% 
cholesterol/DC(8,9)PC specimens gave tubule heights of ~200 nm, as seen in the height profile 
in Figure 5.9.  Tubule height for 40 mole% cholesterol/DC(8,9)PC increases to ~30 nm, as 
shown in Figure 5.10.  Tubule wall thickness appears to depend upon the cholesterol content.   
So, AFM section analysis reveals that above a certain mole% threshold (somewhere above 11%) 
tubule wall thickness increases in an apparently linear fashion upon the addition of cholesterol.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8  Atomic force microscopy section analysis yielding DC(8,9)PC tubule height 
profile.  Tubule height ~100 nm. 
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Figure 5.9  Atomic force microscopy section analysis yielding DC(8,9)PC tubules with 30 
mole% cholesterol tubule height profile.  Tubule height ~200 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10  Atomic force microscopy section analysis yielding DC(8,9)PC tubules with 40 
mole% cholesterol tubule height profile.  Tubule height ~300 nm. 
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5.4 Conclusions 
 Tubule formation persists in the presence of both DOPE and cholesterol, but the 
morphology of the tubules is altered by the presence of these molecules.  DOPE did not cause a 
change in phase or apparently otherwise disrupt the DC(8,9)PC lamellar phase from which 
tubules form, even at concentrations as high as 4:1 DOPE:DC(8,9)PC.  But DOPE is able to 
significantly alter the tubule diameter up to sizes of ~6 µm.  Cholesterol is also able to alter 
tubule morphology with concentrations above a certain mole% threshold (11 mole%).  Above 
this mole% threshold, tubule wall thickness increases in an apparently linear fashion with respect 
to cholesterol concentration.  
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Chapter 6 
Modifying DC(8,9)PC to Create New Tubule-forming Molecules 
6.1 Introduction 
Given the striking correspondence between DC(8,9)PC chirality and the helical sense of 
handedness (helicity) of the tubule exterior, molecular chirality was understandably at the center 
in the development of tubule theory.1-6  But as described in Chapter 1, Thomas et al. developed 
two results inconsistent with these “chiral packing” theories:  1) tubules’ inner cylinder’s helicity 
is random,7 and more strikingly, 2) that molecular chirality is not essential for membrane 
chiralization to occur8. Armed with these new discoveries, we embarked upon developing a 
series of compounds to determine what DC(8,9)PC molecular features enable tubule formation.  
Since it is now known tubules can form from achiral DC(8,9)PC analogs, it is clear that the 
diynes are the enabling feature, and their contribution must be investigated. 
Inspiration is drawn from recent results in liquid crystal physics, namely the so-called 
achiral "banana" or "bow”-shaped molecules that spontaneously form locally-chiral phases, by 
way of a chiral symmetry-breaking transition.9,10  We speculate the tubule forming molecule, 
DC(8,9)PC, may enter such a "bow" conformation by rotations of tail segments about the diyne 
and form chiral mesoscale structures by the same mechanism as the "bow"-shape liquid crystals 
do, shown in Figure 6.1. 
 
 
 
 
Figure 6.1   Represents the tails of the phospholipid rotating about the diyne to enter the 
“bow” confirmation. 
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This hypothesis was tested by synthesizing compounds in which the diynes in the 
DC(8,9)PC tails are replaced by either a cis- or trans- "ene" bond.   When cis ene bonds lie in the 
tails, the hydrocarbon tails are forced into a "bow" shape, but trans ene bonds exclude that 
conformation, and essentially result in a more-or-less straight hydrocarbon tail.  Oleic acid, 
linoleic acid, and γ-linolenic acid (Figure 6.2) were selected as sources for the hydrocarbon tails 
of the phospholipid because of their number of cis bonds.  Oleic acid has one cis bond, while 
linoleic and γ-linolenic acids have two and three, respectively.  This range in the number of cis 
bonds can possibly force a “bow” confirmation to varying degrees as seen in Figure 6.2, if they 
were constrained to lie in a plane, as forced to draw them.  One of three outcomes can be 
expected: 1) The cis- AND trans compounds form tubules; 2) Neither cis- and trans compound 
forms tubules; 3) Only one compound forms tubules.  The cis compounds were selected as a 
starting point, for tubule formation from these compounds would confirm our conjecture, but in 
order to fully understand and confirm this theory, the trans-“ene” bond must be synthesized.  
That is to say, if our “bow” chiral symmetry-breaking model speculation is correct, we expect 
outcome #3, specifically, that the cis compound will form tubules, and that the trans compound 
will not. However, given the primitive state of understanding of tubule formation, outcomes #1 
and #2 and even #3 with the trans compound would be groundbreaking.  
6.2 Synthetic Steps 
6.2.1 Acetonide Protection of Glycerol 
The first step in the synthesis of the DC(8,9)PC derivatives requires protection of the 1,2 
diol on the glycerol backbone shown in Scheme 6.1.  The protected glycerol is made by adding 
an acetonide group and is frequently used for the protection of 1,2 and 1,3 diols.11  Literature 
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provides verification that the 1,2-acetonide is preferred over the 1,3-derivative; however, it is 
structure-dependent.12   
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Figure 6.2  Structures of A. oleic acid, B. linoleic acid, and C. γ-linolenic acid. 
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Scheme 6.1  Acetonide protection of glycerol. 
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6.2.2 Addition of Diethylchlorophosphate  
Phospholipids are synthesized by esterification (Scheme 6.2) of an alcohol to the 
phosphate of phosphatidic acid (1,2-diacylglycerol 3-phosphate).  The third oxygen on glycerol 
is bonded to phosphoric acid through a phosphate ester bond.13,14   
 
 
 
 
Scheme 6.2  Addition of diethylchlorophosphate. 
6.2.3 Deprotection 
 Deprotection of the glycerol backbone, shown in Scheme 6.3, will be achieved through 
hydrolysis of the acetonide, using p-TsOH and ethanol (Scheme 4).11,14 
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Scheme 6.3  Deprotection of glycerol backbone. 
 
6.2.4 Addition of Fatty Acid Tails 
The addition of long chain acids (oleic, linoleic, and γ-linolenic) to glycerol will be 
accomplished via an ester linkage (Scheme 6.4).13,14 
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Scheme 6.4  Addition of fatty acid tails.  
 
6.3 Equipment   
 1H-NMR (400MHz) and 13C-NMR (100MHz) data was acquired on a JOEL JNM-
ECP400 FT-NMR spectrometer, using CDCl3 as the solvent.   
6.4 Synthesis 
6.4.1 Acetonide Protection 
Glycerol (47.6 g, 51.6 mmol), acetone (90 ml), chloroform (200 ml), and p-TSOH (8.9 g, 
5.2 mmol) were added to a round bottom flask attached to a Dean-Stark apparatus and refluxed 
for 10 hours.  The reaction mixture was allowed to cool to room temperature and neutralized by 
stirring with potassium carbonate (3.0 g) for 1 hour.  The reaction mixture was vacuum distilled 
to obtain 3.10 g of 1,2-O-isopropylidene glycerol (2) (74%).  1H-NMR (CDCl3) δ 1.36 (s,3H), 
1.45 (s, 3H), 3.60 (dd, 1H), 3.62 (dd, 1H), 3.97 (dd, 1H), 4.15 (m, 1H).  13C-NMR (CDCl3) δ 
25.3, 26.8, 63.1, 65.8, 76.3, 109.5.  
6.4.2 Addition of Diethylchlorophosphate 
A solution of (2) (6.0 g, 4.5 mmol)  in anhydrous ether/pyridine (12.5 m, 1:1 v/v)  was 
stirred under nitrogen for ~20 minutes at 0o C before adding diethylchlorophosphate (13.19 ml, 
9.1 mmol).  The reaction immediately formed a white precipitate and was stirred for 30 minutes.  
The reaction mixture was poured over 125 g of ice and reached room temperature as the ice 
melted.  An extraction was carried out with 100 ml ether followed by a wash with copper sulfate.  
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The mixture was washed with water, saturated brine, dried with Na2SO4, and filtered.  The 
sample was concentrated under reduced pressure to obtain 5.96 g of phosphate.  The phosphate 
compound (3) was used without further purification.   1H-NMR (CDCl3) δ 1.21-1.52 (m, 12H), 
2.07-2.33 (m, 2H), 3.67 (dd, 1H), 4.15 (m, 5H), 4.30 (m, 1H). 
6.4.3 Deprotection   
A mixture of (3) (2.96 g, 11 mmol) and p-toluenesulfonic acid (326 mg, 1.6 mmol) in 
ethanol (85 ml), was refluxed for 14 hours under Nitrogen at room temperature.  Sodium 
bicarbonate was added to the reaction to neutralize the acid.  The mixture was filtered and placed 
on the rotovap.  The residue was re-dissolved in chloroform (50 ml) and filtered through Celite 
before concentrating under reduced pressure, yielding 1.99 g (79%).  The material was used 
without further purification (4). 1H-NMR (CDCl3) δ 1.25 (dd, 6H), 2.12 (m, 2H) 3.40 (dd, 1H), 
3.68 (dd, 2H), 4.10 (m, 5H), 4.20 (m, 1H). 13C-NMR (CDCl3) δ 16.3, 61.1, 66.5, 69.8, 75.3.  
6.4.4 Addition of Fatty Acid Tails 
6.4.4.1 (9Z,9`Z)-3-(diethoxyphosphoryloxy)propane-1,2-diyl dioctadec-9-enoate 
A solution of deprotected starting material (4) (1.99 g, 9.5 mmol) and 1,3-
dicyclohexylcarbodiimide (4.31 g, 21.0 mmol) in methylene chloride (7 ml) was stirred before 
adding pyridine (0.14 g, 1.7 mmol), oleic acid (5.64 g, 19 mmol), and more methylene chloride 
(35 ml).  The mixture was stirred under Nitrogen for 48 hours at room temperature.  After 
reaction was complete, the mixture was filtered over Celite and placed on the rotovap.  The 
concentrated material was then re-dissolved in hexane, filtered again over Celite, and evaporated 
to yield 5.09 g (71%) of yellow oil (5).  The purification of the oil was carried out by flash 
chromatography on silica gel using hexane/ethyl acetate (10:1).  1H-NMR (CDCl3) δ 0.86 (t, 
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5H), 1.23-1.97 (m, 58H), 2.28-2.37 (m, 10H), 4.06-4.13 (m, 6H), 5.31 (m, 8H)  13C-NMR 
(CDCl3) δ 14.2, 22.7, 24.8, 25.4, 26.5, 29.5, 31.2, 32.0, 76.8, 77.1, 77.4, 128.1, 130.2, 155.2.  
6.4.4.2 (9Z,9'Z,12Z,12'Z)-3-(diethoxyphosphoryloxy)propane-1,2-diyl dioctadeca-9,12-
dienoate 
 
 A solution of deprotected starting material (4) (1.70 g, 8.1 mmol) and 1,3-
dicyclohexylcarbodiimide (3.69 g, 17.9 mmol)) in methylene chloride (7 ml) was stirred before 
adding pyridine (0.14 g, 1.7 mmol), linoleic acid (4.8 g, 17.1 mmol), and more methylene 
chloride (35 ml).  The mixture was stirred under Nitrogen for 48 hours at room temperature.  
After reaction was complete, the mixture was filtered over Celite and placed on the rotovap.  The 
concentrated material was then re-dissolved in hexane, filtered again over Celite, and evaporated 
to yield 4.12 g (65%) of yellow oil (5), which was used without further purification for tubule 
studies.   1H-NMR (CDCl3) δ 0.90 (t, 6H), 1.11-1.84 (m, 53H), 2.01-2.29 (m, 8H), 4.09 (m, 6H), 
4.21 (dd, 2H), 5.3 (m, 8H).    13C-NMR (CDCl3) δ.14.2, 22.7, 24.8, 25.7, 27.3, 29.4, 30.9, 49.8, 
76.8, 77.3, 128.1, 130.3, 154.2. 
6.4.4.3 (6Z,6`Z,9Z,9'Z,12Z,12'Z)-3-(diethoxyphosphoryloxy)propane-1,2-diyl dioctadeca-
6,9,12-trienoate 
 
 A solution of deprotected starting material (4) (0.272 g, 1.3 mmol) and 1,3-
dicyclohexylcarbodiimide (0.621 g, 3 mmol) in methylene chloride (7 ml) was stirred before 
adding pyridine (21.5 mg, 0.03 mmol), γ-linolenic acid ((0.80 g, 2.9 mmol) 4.8 g, 17.1mmol), 
and more methylene chloride (35 ml).  The mixture was stirred under Nitrogen for 48 hours at 
room temperature.  After reaction was complete, the mixture was filtered over Celite and placed 
on the rotovap.  The concentrated material was then re-dissolved in hexane, filtered again over 
Celite, and evaporated to yield 1.14 g (51%) of yellow oil (5), which was used without further 
purification for tubule studies.   1H-NMR (CDCl3) δ 0.91 (t, 6H), 1.08-1.89 (m, 43H), 2.00-2.43 
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(m, 10H), 3.92 (m, 6H), 4.12 (dd, 2H), 5.31 (m, 12H). 13C-NMR (CDCl3) δ 14.1, 22.7, 23.9, 
25.7, 27.2, 29.4, 30.9, 32.9, 77.5, 128.2, 129.7, 130.5, 172.1.  
 
6.5 Results 
The oleic acid tail compound (containing one cis moiety per tail), (9Z,9`Z)-3-
(diethoxyphosphoryloxy)propane-1,2-diyl dioctadec-9-enoate,  was studied first to test if tubules 
could form from molecules forced to be in the “bow” shape.  Originally, the new compound was 
treated as DC(8,9)PC, adding 1 mg/ml of solution (ethanol:water, 75:25).  Upon this preparation, 
the solution was immediately clear, revealing that the material was completely dissolved, even 
before heating.  Since DC(8,9)PC tubules are present at room temperature, this result was not 
very promising.  The sample was then titrated with water, in order to make the compound less 
soluble in the solution.  A total of 1835 µl was added before the material became cloudy, 
practically reversing the solvent ratio (ethanol:water 26:74), at room temperature.  As the 
mixture was heated to 45oC, it turned cloudier. (Upon heating the comparable DC(8,9)PC 
solution to this temperature, it becomes clear).  The oleic-acid-based compound mixture finally 
turned clear at ~70 oC, indicating that the compound was now in solution.  Upon returning back 
to room temperature, the solution remained clear, indicating that the material was still in solution 
and no tubules had precipitated.  As a last measure, the mixture was put in the freezer (~5oC) for 
~1 hour in order to induce the phase transition to tubules.  Indeed, the solution became cloudy 
and was examined by optical microscopy, where a small number of tubules (Figure 6.3) and 
some other irregular structures (Figure 6.4) were seen.  While this is not the robust DC(8,9)PC 
outcome, tubules are indeed present, strongly supporting the notion that the “bow” conformation 
is necessary for tubule formation. 
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Figure 6.3  100 µm x 100 µm atomic force micrograph of new tubule-forming compound, 
showing that some tubules are present.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4  100 µm x 100 µm atomic force micrograph of new tubule-forming compound, 
showing rigid, sheet-like structures.   
 
It is not clear if this lower phase transition temperature is a kinetics effect or a 
consequence of using a solvent system that happens to be far from optimal for this new 
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molecule; it is possible that both are in play.  Supporting the idea that this molecule’s tubule 
formation kinetics are slow is the observation that once formed, the tubules did not melt at room 
temperature, and that going far below the Lα-to-Lβ′ transition temperature simply sped up the Lα-
to-Lβ′ phase transition.  As far as the notion that solvent composition may require optimization is 
the observation that methanolic and propanolic DC(8,9)PC solutions produce somewhat different 
self-assembly structures than ethanolic ones; it is natural to assume that this new molecule’s 
optimum solvent composition might be different from that of DC(8,9)PC.  
The 10-15 µm diameter tubules that are present are much larger than the traditional 0.5 
µm DC(8,9)PC tubule.  Figure 6.4 shows some objects that are not completely understood at this 
point in time.  They appear to be sheets similar to those formed by DC(8,9)PC shown in Figure 
1.4, from which tubules form, but we cannot exclude the possibility this is merely bulk crystal.  
It is possible for sheets to exist and tubules not to form, but in this case, it seems that both the 
sheets and tubules are present.     
Several combinations of ethanol/ water and varying the amount of lipid were investigated 
in order to discover the optimum conditions for normal tubule precipitation to occur with this 
new compound.  Figure 6.5A and 6.5B and show the well-known “starburst” pattern left after an 
Lα spherical vesicle has radiated from a center (the spherical vesicle) and been completely 
converted to tubules. Several of these clusters can be seen in Figure 6.5A.  Both Figures 6.5A 
and 6.5B scans are representative of the entire sample as indicated by the two completely 
different areas that are showing this starburst phenomenon.  Another critical structure in these 
micrographs is the presence of a faint, thin but large sheet in the midst of these clusters.  This 
structure is tentatively interpreted to be the flat sheet from which tubules can form, as discussed 
in Section 1.1.3.3.   
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A.                                                                              B. 
 
 
Figure 6.5  A. and B. 100 µm x 100 µm atomic force micrograph of new tubule-forming 
molecule, arrows are pointing to sheets.   
 
 
6.6 Conclusions 
In conclusion, the new compound containing oleic acid tails formed tubules.  The 
conditions for this initial study are certain to not be optimized, but this early success with this 
compound indicates that triple bonds are not necessary for tubule formation, and suggest 
powerfully that the hydrocarbon tail segments attached to the triple bonds present tails in a 
“bow” configuration, and that the chiral symmetry-breaking theory developed for “banana” 
liquid crystals may now be the best starting point for developing a general tubule structure and 
formation theory.  As seen in the images above, tubules can be obtained without diynes in the 
tails, but instead with a cis ene bond present that forces the molecule into a “bow” shape.   
Another important factor to point out is that this new tubule-forming phospholipid has an 
ester headgroup, instead of a choline headgroup as in DC(8,9)PC, proving further that the 
headgroup has little, if any effect whether tubule formation is possible.  It is likely that the shape 
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and charge distribution of the choline headgroup may further enhance the packing of the 
phospholipids, and it may possibly yield tubules in greater numbers.  There is still much to be 
studied about these compounds, including investigation of the linoleic and γ-linolenic acid tails, 
along with synthesizing the expected counter-example trans-“ene” compounds that cannot access 
“bow” configurations.     
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Chapter 7 
Conclusions and Future Work 
7.1 Conclusions 
7.1.1 A New Tubule Formation Intermediate: The Tubelet 
Perhaps the most important result reported in this dissertation, both in terms of theory and 
application, is the discovery of the structure we call the “tubelet,” a previously-unobserved 
structure, apparently the precursor to the tubule.1 This structure was serendipitously discovered 
through the addition of lysozyme at approximately 1 mg protein / ml DC(8,9)PC stock solution 
during the standard tubule formation thermal cycling.  Lysozyme’s presence unexpectedly 
promoted crack formation in the drying droplet of sample placed atop a carbon electron 
microscopy stem.  Probing these cracks in the deposition bed with scanning electron microscopy 
allowed unprecedented detailed examination of the liquid specimen’s interior, which was 
exposed at the crack interface in a manner similar to conventional freeze-fracture techniques.  
The slow and gentle surface-cracking behavior exposes these structures for extended lengths into 
free space – completely eliminating the background of the dried specimen and the dense thicket 
of other structures it contains.  This remarkable stroke of luck allows clear and unambiguous 
characterization of these previously unobserved tubelets over lengths up to approximately 50 
microns. 
This discovery shows that tubules are not comprised of a helically-wound flat bilayer 
membrane at all,2 but are instead formed by flattened tubelets, whose structure is topologically 
much more complex than a phospholipids bilayer ribbon.  The tubelet may be thought of as a 
flattened firehose, where the firehose wall is composed of a phospholipids bilayer.  Such a 
structure explains a number of otherwise difficult-to-justify tubule features, such as the 
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extraordinarily high aspect ratio of the tubule precursor.  That is, the simple phospholipids 
bilayer ribbon has hydrocarbon tails exposed to the aqueous environment along its enormous 
perimeter, while the tubelet is edge-free (except perhaps for the circular cross-sections at the 
tubelet’s ends).  Another behavior that is well-explained by the tubelet as a tubule precursor is 
the tightly-conserved interlamellar spacing found in tubules whose diameters may differ by a 
factor of 5, or by tubules made by DC(8,9)PC derivatives:3,4 the interlamellar spacing is a 
reflection of the collapsed firehose spacing, and not of independent, coaxial phospholipids 
bilayer ribbons. 
The tubelet structure also provides critical new insights regarding the use of tubules as 
drug delivery vehicles.  This is so because the ~0.5 µm diameter DC(8,9)PC tubule could easily 
be dismissed as encapsulation agents because their diameter is too great to provide significant 
drug retention time.  But, the secondary winding of a smaller tube (that is, the tubelet), and the 
more convoluted exit pathway an encapsulant must traverse are expected to greatly enhance 
retention times over that expected from a simple cylinder.   
7.1.2 Encapsulation Studies with Chemotherapy Agents 
The encapsulation studies reported in this dissertation demonstrate that it is possible to 
form tubules in the presence of a variety of chemotherapy agents, and do so at clinically-relevant 
concentrations.  Methotrexate, mitoxantrone, and carboplatin did not significantly hinder tubule 
formation, but in all three cases, the drugs did exert significant effects upon tubule morphology.  
This implies significant drug/tubule interaction, and as discussed, in the carboplatin case, EDS 
unambiguously shows this interaction is indeed encapsulation, or at the very least, strong 
association with the tubule surface. 
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When any of these 3 chemotherapy agents are present at concentrations of approximately 
28 weight%, tubule yield drops precipitously and non-tubule structures appear that are not seen 
in drug-free DC(8,9)PC samples or drug-containing samples at lower concentrations.  These 
structures are presumably co-precipitated lipid, drug, or some mixture of the two.  It is found that 
tubule diameter increases upon the addition of any of these drugs over the concentration range 
studied; this outcome strongly suggests that the drugs decrease the membrane’s intrinsic 
curvature, the hallmark feature of tubule formation.  In turn, this diameter increase is most easily 
interpreted as interference with the tubule formation mechanism, most likely by incorporation of 
the drug into the membrane, but the possibility of strong association between the drug and the 
membrane’s headgroups cannot be dismissed from our data.  
As mentioned, carboplatin presents a special opportunity, for it contains platinum, and 
energy dispersive spectroscopy (EDS) can be used to easily locate the carboplatin without the 
possibility of confusing it with other metals present in the electron microscopy grid.  The 
carboplatin was found to be in (or, as we must permit, possibly on), the tubules or within the 
region around the tubule that is defined by the EDS spatial resolution.  A centrally important fact 
from the EDS spectroscopy is that there is essentially no platinum found away from the tubule.  
This absence of Pt in specimen regions lying between tubules merits special comment. 
We know that tubules fall to the bottom of the droplet within minutes after its deposition 
on the electron microscopy stem, and the droplet dries over the course of time.  As the droplet 
dries, the solution, which contains DC(8,9)PC “monomer” and carboplatin in equilibrium with 
the DC(8,9)PC/carboplatin tubules forms a round, waxy disk, with the tubules lying at the 
bottom of the disk.  That is to say, these inter-tubule regions represent significant amounts of the 
solution, considering that the droplet is initially about 1 mm in height (compared to the 0.5 µm 
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DC(8,9)PC tubule diameter). That EDS spectroscopy failed to detect Pt in these regions suggests 
that tubules are voraciously effective as carboplatin encapsulants. 
Although the three drugs mentioned above permitted tubule formation at clinical 
concentrations, an example of a drug that was a powerful inhibitor of tubule formation is 
bleomycin, a mixture of cytotoxic glycopeptide antibiotics, which is isolated from a strand of 
bacteria found in soil and dying vegetation, Streptomyces verticillus.5  Given that tubules were 
merely distorted into cones by lysozyme, it is important to understand why this bleomycin is so 
potent an inhibitor of tubule formation.     
7.1.3 Optimization of Phospholipid Tubule Morphology 
Optimizing tubule properties, such as their dimension, for a particular application by 
adding a co-surfactant or other small molecule, could be necessary in drug delivery, either to 
counter the drug’s own effects upon tubule morphology, or perhaps to enhance these effects. 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) was selected as a co-surfactant 
in order to determine how it might affect tubule morphology.  This choice was made because 
DOPE is known to induce an inverse hexagonal phase.6,7  Interestingly, DOPE did not affect 
tubule formation, even at the very high [DOPE:DC(8,9)PC] concentrations of 4:1.  DOPE did, 
however, cause a dramatic increase in tubule diameter, ranging from 0.5 µm to some 6 µm, 
within a single sample.  These larger tubules could possibly increase the drug loading capacity of 
a given tubule; dosage to the patient would accordingly be adjusted by decreasing the number of 
tubules dispensed.  
Another molecule known to modify membrane structure, cholesterol, was used to 
determine if it would have an effect on tubule formation.  Cholesterol is known to increase 
bilayer thickness in phospholipids and increase membrane fluidity.8-11  As discussed in Chapter 
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5, AFM section analysis shows directly that it was able to do so with DC(8,9)PC, and the tubules 
did exhibit an in increase in bilayer thickness from 100 nm up to 200 and 300 nm upon the 
addition of 30 and 40 mole% respectively.    
7.1.4 Modifying DC(8,9)PC to Create New Tubule-forming Molecules 
A completely different, but far more labor-intensive approach to regulating tubule 
structure is to modify the tubule-forming molecule.  For example, Thomas et al. demonstrated 
that changing the headgroup was successful in altering tubule morphology, creating tubules with 
larger diameters.3,4 
We chose to synthesize a class of compounds whose design was inspired by results from 
liquid crystal physics.   The new compounds were designed to test whether the tails’ diynes are 
the feature that enables tubule formation.  Specifically, the reason that the diynes enable tubule 
formation may be that they enable DC(8,9)PC tails to enter into the “bow” confirmation 
described by Clark et al.12,13 
Three compounds were made with at least one cis bond in their tails, in order to force a 
“bow” confirmation; the counter-example would be the corresponding trans compounds which 
cannot enter a “bow” configuration.  Studies of the first compound, with oleic acid tails 
(9Z,9`Z)-3-(diethoxyphosphoryloxy)propane-1,2-diyl dioctadec-9-enoate, indicate that tubule 
formation is possible from these “ene” compounds, and that the “bow” chiral symmetry-breaking 
mechanism described by Clark is the mechanism that chiralizes the tubule-forming membrane.  
Interestingly, tubules produced by this compound are significantly larger (~10-15 µm range).  
Another feature of great interest seen in the sample are large sheets, which we tentatively 
interpret as being the sheets from which ribbons separate edge-wise from the sheet’s long edge.  
It is important to note that our compound does not have a polar headgroup, as in the case of 
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DC(8,9)PC, which further illustrates that the “bow” confirmation in the tails is what allows 
tubule formation. 
7.2 Future Work 
There is still much to be learned about tubule formation and morphology in order to 
efficiently develop tubules for potential applications.  Although the chemotherapy agents were 
able to increase tubule diameter, leading us to believe that the drug is possibly entering the 
membrane or interfering with the membrane chiralization, thereby increasing tubule diameter.  
To optimize tubule morphology for drug encapsulation, it will be important to locate exactly 
where the drug resides.  EDS was used in the case of carboplatin, but other methods (such as 
small angle x-ray scattering) could also be used to confirm this result and determine the location 
of the other drugs, methotrexate and mitoxantrone.  SAXS can give information about membrane 
spacing and the extent over which this spacing is conserved.  This information would allow us to 
infer where the drug is located.  NMR can also be used to determine if encapsulation has been 
successful.  A sample can be prepared with the drug, thoroughly washed with water to ensure 
that any drug that remained in the solution will no longer be present, centrifuged to get a pellet, 
and then examined with standard liquid NMR techniques.  Because tubules are crystalline, and 
are very large and hence stationary, the encapsulated drug should not be able to tumble freely, 
and this anisotropic condition should result in essentially no detectable NMR signal.  Such a 
sample can then either be titrated with ethanol in order to dissolve the tubule, or simply heated 
above the spherical vesicle formation temperature, releasing any drug located in the membrane 
into solution. In either case, if drug is released from the solid tubule phase into solution, it will 
show up on the NMR spectra.  Subtler questions regarding the location, orientation and 
conformation of the drug can be answered using MAS or solid-state NMR, but the use of simple, 
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conventional liquid NMR techniques as described to find if there is any drug in the membrane is 
a sensible first step.   
The successful incorporation of cholesterol into the membrane of DC(8,9)PC serves as a 
model for the incorporation of other important, closely-related compounds.  For instance, 
hormones having similar structures to that of cholesterol (testosterone, progesterone, etc.), 
should be studied in order to determine if tubules can be used as vehicles for these types of 
amphipathic compounds.  Also, the fact that cholesterol was able to increase bilayer thickness 
may prove useful for expanding the hydrophobic regions in the tubule, thus creating a larger 
space for hydrophobic drugs to reside.  After the addition of cholesterol, water insoluble drugs 
should be added to determine if drug loading can be increased.   
We have shown tubules form from a compound that is structurally significantly different 
from DC(8,9)PC.  The oleic acid tail compound should be investigated further to determine its 
optimal conditions for tubule formation.  Along with these studies, the other two compounds 
with linoleic acid and γ-linolenic acid, must be investigated.  In order to fully prove the “bow” 
conformation theory of tubule formation, the trans compounds must be made.  While the 
expected outcome is no tubule formation, this “null” result must be demonstrated under a wide 
range of conditions before we can be confident it is in fact correct.  
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Supplemental NMR Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1  1H-NMR of 6.4.4.1. 
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Figure A.2  13C-NMR of 6.4.4.1. 
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Figure A.3  1H-NMR of 6.4.4.2. 
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Figure A.4  13C-NMR of 6.4.4.2. 
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A.5  1H-NMR of 6.4.4.3. 
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